

Weekly

August 11, 2006 / Vol. 55 / No. 31

The Global HIV/AIDS Pandemic, 2006

Since the first cases of acquired immunodeficiency syndrome (AIDS) were reported in 1981, infection with human immunodeficiency virus (HIV) has grown to pandemic proportions, resulting in an estimated 65 million infections and 25 million deaths (1,2). During 2005 alone, an estimated 2.8 million persons died from AIDS, 4.1 million were newly infected with HIV, and 38.6 million were living with HIV (2). HIV continues to disproportionately affect certain geographic regions (e.g., sub-Saharan Africa and the Caribbean) (Figure) and subpopulations (e.g., women in sub-Saharan Africa, men who have sex with men [MSM], injection-drug users [IDUs], and sex workers). Effective prevention and treatment of HIV infection with antiretroviral therapy (ART) are now available, even in countries with limited resources (2). Nonetheless, comprehensive programs are needed to reach all persons who require treatment and to prevent transmission of new infections.

This report, published on the eve of the sixteenth International AIDS Conference (August 13–18, 2006, in Toronto, Canada), summarizes selected regional trends in the HIV/AIDS pandemic, based largely on data from the 2006 *Report on the Global AIDS Epidemic* by the Joint United Nations Programme on HIV/AIDS (UNAIDS) (2). Related reports in this issue of *MMWR* describe the prevalence of HIV infection among MSM in Thailand, HIV-related practices at chest clinics in Guyana, and HIV-related risk behaviors among high school students in the United States.

Sub-Saharan Africa. Approximately 10% of the world population lives in sub-Saharan Africa, but the region is home to approximately 64% of the world population living with HIV (2). Transmission is primarily through heterosexual contact, and more women are HIV infected than men. Southern Africa is the epicenter of the AIDS epidemic; all countries in the region except Angola have an estimated adult (i.e., aged 15–49 years) HIV prevalence exceeding 10% (2). In Botswana,

Lesotho, Swaziland, and Zimbabwe, the estimated adult HIV prevalence exceeds 20% (2). South Africa, with an HIV prevalence of 18.8% and 5.5 million persons living with HIV, has, along with India, the largest number of persons living with HIV in the world (2). Recently, declines in adult HIV prevalence have been observed in Kenya, Uganda, Zimbabwe, and urban areas of Burkina Faso. Although in these countries, HIV-related sexual risk behaviors and HIV incidence have decreased, AIDS death rates continue to rise. In sub-Saharan Africa, 17% of the estimated number of persons in need of ART received it in 2005 (*3*).

Asia. Adult HIV prevalence is lower in Asian countries than in countries in sub-Saharan Africa, and the epidemic in most Asian countries is attributable primarily to various high-risk behaviors (e.g., unprotected sexual intercourse with sex workers, IDUs, or MSM and injection-drug use). Of the 8.3 million HIV-infected persons in Asia, 5.7 million live in India, where the prevalence varies by state. Approximately 80% of HIV infections in India are acquired heterosexually. Recent data from four Indian states indicated a decline in HIV prevalence among pregnant women aged 15–24 years, from 1.7% in 2000 to 1.1% in 2004 (4). In China, where 650,000 IDUs

INSIDE

- 844 HIV Prevalence Among Populations of Men Who Have Sex with Men — Thailand, 2003 and 2005
- 849 HIV Counseling, Testing, and Care of Tuberculosis Patients at Chest Clinics — Guyana, 2005–2006
- 851 Trends in HIV-Related Risk Behaviors Among High School Students — United States, 1991–2005
- 854 Vibrio parahaemolyticus Infections Associated with Consumption of Raw Shellfish — Three States, 2006
- 856 Notice to Readers
- 857 QuickStats

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2006;55:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH *Director* Tanja Popovic, MD, PhD (*Acting*) Chief Science Officer

James W. Stephens, PhD (Acting) Associate Director for Science

Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing Judith R. Aguilar

(Acting) Director, Division of Health Information Dissemination (Proposed)

Editorial and Production Staff

Frederic E. Shaw, MD, JD (Acting) Editor, MMWR Series Suzanne M. Hewitt, MPA

Managing Editor, MMWR Series Douglas W. Weatherwax (Acting) Lead Technical Writer-Editor

Catherine H. Bricker, MS Jude C. Rutledge Writers-Editors

Beverly J. Holland Lead Visual Information Specialist Lynda G. Cupell Malbea A. LaPete

Visual Information Specialists Quang M. Doan, MBA Erica R. Shaver Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Stanley A. Plotkin, MD, Doylestown, PA Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

account for approximately half of persons living with HIV infection; in contrast, the epidemics in Thailand and Cambodia have been driven largely by commercial sex. In Thailand, HIV prevalence in pregnant women declined from 2.4% in 1995 to 1.2% in 2003. However, HIV prevalence among MSM in Bangkok increased from 17% in 2003 to 28% in 2005 (*5*). Only 16% of persons in need of ART in Asia received it in 2005 (*3*).

Americas. HIV infections are reported mostly among MSM, IDUs, and sex workers in the Americas. Brazil, the second most populous country in the Americas (after the United States), has an adult HIV prevalence of 0.5% and has approximately 30% of the population living with HIV in South and Central America and the Caribbean. High-risk behavior among Brazilians aged 15-24 years remains high; one in three report initiating sexual activity before age 15 years, and one in five report having had more than 10 sex partners. Brazil provides free ART to all in need of treatment, and approximately 83% of HIV-infected persons receive therapy. After sub-Saharan Africa, the Caribbean is the second most HIV-affected region of the world. Like sub-Saharan Africa, HIV transmission in the Caribbean is largely heterosexual. HIV prevalence has declined in urban areas of Haiti but has remained constant in other areas of the Caribbean. Overall in South and Central America and the Caribbean, approximately 68% of persons in need of ART received it in 2005 (3).

In the United States, recent evidence suggests a resurgence of HIV transmission among MSM; during 2001–2004, an estimated 44% of new HIV infections were in MSM, and 17% were in IDUs (6). In addition, blacks and Hispanics together account for 69% of all reported HIV/AIDS cases. In the United States, 55% of persons in need of ART received it in 2005.

Reported by: World Health Organization, Geneva, Switzerland. Interagency Surveillance and Survey Working Group, Office of the US Global AIDS Coordinator, US Dept of State. Div of Global AIDS, National Center for HIV, Viral Hepatitis, STDs, and Tuberculosis Prevention (proposed), CDC.

Editorial Note: This report summarizes certain regional trends in the HIV/AIDS pandemic, which has reversed the course of human development (7) and eroded improvements in life expectancy in countries with the highest prevalence of infection (2). The greatest HIV burden is in sub-Saharan Africa, home to 15 countries with the highest prevalence of HIV infection in the world. In most other regions, HIV infections have been concentrated in various high-risk populations. To be effective, prevention measures must be tailored to the local epidemiology of HIV infection, based on the behaviors and exposures associated with new transmission.

MMWR




FIGURE. Estimated percentage of adult population* living with human immunodeficiency virus (HIV) infection, by country — worldwide, 2005[†]

SOURCE: Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS; 2006. Available at http://www.unaids.org/en/hiv_data/2006globalreport/default.asp. *Aged 15–49 years.

The worldwide estimate of the number of persons living with HIV is 38.6 million.

From 2003 to 2005, estimates of adult HIV prevalence were lowered in many countries. Some of these reductions might be attributable to the addition of new surveillance sites and population-based surveys that provide better estimates in rural populations, which usually have lower HIV prevalence. However, some countries (including Kenya, Uganda, Zimbabwe, and urban parts of Burkina Faso and Haiti) have reported evidence of actual declines in HIV prevalence. Changes in sexual behavior (e.g., delayed initiation of sexual intercourse, decrease in number of sex partners, or increase in condom use) appear at least partly responsible for these declines, although increasing mortality might have been a contributing factor (*8*).

During 2003–2005, substantial gains were made in the number of persons receiving ART in resource-limited countries (3). The "3 by 5" initiative, a strategy of the World Health Organization and UNAIDS, sought to provide treatment to 3 million persons (50% of those in need of treatment worldwide) in low- and middle-income countries by 2005. By December 2005, 18 countries had met their "3 by 5" target, and the number of persons receiving ART had increased from

400,000 in December 2003 to 1.3 million (3). Overall, this 225% increase can be attributed to commitments by the President's Emergency Plan for AIDS Relief (PEPFAR); the Global Fund To Fight AIDS, Tuberculosis, and Malaria; and the World Bank. By the end of March 2006, PEPFAR supported ART for 561,000 persons in 15 countries (9).

Despite the gains in ART, only 20% of persons in need of treatment in low- and middle-income countries were receiving it in December 2005 (*3*). Despite a 5-year scale-up of interventions to prevent mother-to-child transmission (PMTCT) of HIV, approximately one in 10 pregnant women were offered PMTCT services, and fewer than one in 10 HIV-positive pregnant women received ART prophylaxis for PMTCT (*2*). Expansion of HIV testing, including the routine offer of testing and counseling in clinical settings, will be needed to identify more persons in need of ART and PMTCT services; improvements in infrastructure and human resources will be needed to deliver quality services to the increasing number of persons requiring treatment. As more HIV-infected persons receive ART, the number of persons living with HIV infection will increase, requiring that prevention programs scale

up to prevent HIV transmission from those living with HIV infection and for those at risk for infection. Prevention measures directed toward populations most likely to be exposed to HIV in low-level and concentrated epidemics* and toward young persons and those with HIV infection in generalized epidemics must be scaled up in parallel with care and treatment programs.

To maximize the effectiveness of HIV/AIDS programs, the quality and coverage of services should be evaluated, and the success of interventions should be assessed by analyzing trends in morbidity, mortality, and behaviors of populations infected with HIV or at risk for HIV infection. Using these data to modify and improve HIV/AIDS programs, an approach integrating prevention and treatment is being developed that could reduce treatment need by as much as 50% by 2020 (*10*).

References

- 1. CDC. Pneumocystis pneumonia-Los Angeles. MMWR 1981;30:250-2.
- Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 report on the global AIDS epidemic. Geneva, Switzerland: UNAIDS; 2006. Available at http://www.unaids.org/en/hiv_data/2006global report/default.asp.
- 3. World Health Organization, Joint United Nations Programme on HIV/ AIDS (UNAIDS). Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond, 2006. Geneva, Switzerland: World Health Organization, Joint United Nations Programme on HIV/ AIDS (UNAIDS); 2006. Available at http://www.who.int/hiv/full report_en_highres.pdf.
- Kumar R, Jha P, Arora P, et al. Trends in HIV-1 in young adults in south India from 2000 to 2004: a prevalence study. Lancet 2006;367: 1164–72.
- CDC. HIV prevalence among men who have sex with men— Thailand, 2003–2005. MMWR 2006;55:844–8.
- 6. CDC. Trends in HIV/AIDS diagnosis—33 states, 2001–2004. MMWR 2005;54:1149–53.
- United Nations Development Programme. Human development report, 2005. International cooperation at a crossroads: aid, trade and security in an unequal world. New York, NY: United Nations Development Programme; 2005. Available at http://hdr.undp.org.
- Hallett TB, Aberle-Grasse J, Bello G, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect 2006;82(Suppl 1):i1–i8.
- Office of Global AIDS Coordinator. U.S. President's Emergency Plan for AIDS Relief. Making a difference: supporting antiretroviral treatment, 2006. Washington, DC: Office of Global AIDS Coordinator; 2006. Available at http://www.state.gov/documents/organization/ 67502.pdf.
- 10. Salomon JA, Hogan DR, Stover J, et al. Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2005;2:e16.

HIV Prevalence Among Populations of Men Who Have Sex with Men — Thailand, 2003 and 2005

In 2003 and 2005, the Thailand Ministry of Public Health -U.S. Centers for Disease Control and Prevention Collaboration and its partners conducted surveillance of human immunodeficiency virus (HIV) prevalence and risk factors among populations of men who have sex with men (MSM) in Thailand. In 2003, the assessment was conducted in Bangkok among a sample of MSM* (1). In 2005, in addition to Bangkok, the assessment was conducted in Chiang Mai and Phuket provinces, and participants were categorized as MSM, male sex workers (MSW), or transgendered persons (TG). This report compares HIV prevalence among MSM in Bangkok during 2003 and 2005, reports HIV prevalence among the three populations in 2005, and summarizes the results of univariate and multivariate analysis of risk factors for HIV infection in 2005. The results indicated a significant increase in HIV infection among MSM in Bangkok from 2003 to 2005. The findings also indicated that in 2005, HIV infection was widespread among MSM, MSW, and TG in the three study locations. Moreover, the following risk factors were independently associated with HIV infection: being recruited from Bangkok or Chiang Mai (MSM), older age (MSM and TG), being recruited from a park or street location (MSW and TG), drug use (MSM), self-reporting a history of sexually transmitted infections (MSW), and self-reporting a previous HIV-positive test result or refusing to disclose a previous HIV test result (MSM and MSW). Sex with women during the preceding 3 months was inversely associated with HIV prevalence among MSW. More effective behavioral and biomedical interventions for MSM, MSW, and TG are needed to stop the spread of HIV in these populations.

Using venue-day-time sampling[†] (1,2), participants were enrolled from locations where MSM, MSW, and TG congregate to socialize and seek sex partners and clients, including entertainment venues (e.g., bars and discos), parks, saunas, street locations, and sex-work venues (e.g., "go-go" bars [i.e., bars where sex workers can be solicited] and massage parlors). Venues and participants were selected by using a systematic process of mapping and visiting venues, enumerating attendance at different times and days, and determining eligibility of participants and their willingness to participate (1,2).

^{*} WHO and UNAIDs define these three types of epidemics as follows: low level: HIV prevalence has not consistently exceeded 5% in any defined subpopulation; concentrated: HIV prevalence is consistently >5% in at least one defined subpopulation and is <1% in pregnant women in urban areas, and generalized: HIV prevalence is consistently >1% in pregnant women.

^{*} In this report, MSM refers to men who have sex with men but who were not

enrolled at venues where male sex workers or transgendered persons congregate. [†] Sampling method specifically designed to access hard-to-reach or "hidden" populations such as MSM.


To participate, a person had to be Thai, male at birth, a resident of the study area, and aged ≥ 15 years (≥ 18 years for the 2003 study) and had to have engaged in anal or oral sex with a man during the preceding 6 months. Participation was voluntary and anonymous, and oral informed consent was required. In 2003, an interviewer-administered questionnaire was used, and in 2005, a self-administered questionnaire was used to collect demographic and behavioral information, which was completed using handheld computers. Oral fluid specimens were collected using the OraSure[®] device and tested at a 1:2 dilution in single wells by an enzyme immunoassay (EIA). Positive samples were retested in duplicate, and two or more positive wells were reported as oral fluid anti-HIV positive (1). Oral HIV test results were available to participants who, if determined to be HIV positive, were referred for confirmatory EIA serum testing and appropriate HIV treatment and care according to Thai national guidelines (3).

In 2003, a total of 1,121 Thai MSM were enrolled from 14 venues in Bangkok (enrollment rate: 90.2%) (1); in 2005, a total of 2,049 Thai men were enrolled from 106 venues in Bangkok, Chiang Mai, and Phuket (enrollment rate: 97.3%). Of the latter sample, 821 were categorized as MSM, 754 as MSW, and 474 as TG.

In Bangkok, the overall HIV prevalence among MSM increased from 17.3% (95% confidence interval [CI] = 15.1%–19.7%) in 2003 to 28.3% (95% CI = 23.9%–33.0%) in 2005 (Figure). A statistically significant increase (p<0.05; assessed by χ^2 test) in HIV prevalence in Bangkok was observed among MSM at entertainment venues and saunas and in all age groups. In 2005, in Bangkok, 22.3% of MSM aged 15–22 years, 30.5% of MSM aged 23–28 years, and 29.7% of MSM aged \geq 29 years were infected with HIV.

In 2005, the HIV prevalence among MSM was 15.3% in Chiang Mai and 5.5% in Phuket (Table). In 2005, the HIV prevalence among MSW was 18.9%, 11.4%, and 14.4% in Bangkok, Chiang Mai, and Phuket, respectively. HIV prevalence among TG was 11.5%, 17.6%, and 11.9% in Bangkok, Chiang Mai, and Phuket, respectively. HIV prevalence among MSM differed significantly among the three study areas ($\chi^2_{df=2} = 47.67$; p<0.001); no such differences were observed among MSW and TG.

In 2005, among MSM, the following factors were significantly associated with HIV prevalence in univariate analysis: residing in Bangkok or Chiang Mai, older age, recruitment from an entertainment venue or sauna, homosexual or bisexual self-identification, both insertive and receptive anal intercourse, self-reported genital ulcer or discharge (ever), selfreported drug use (ever), refusal to disclose a previous HIV test result, and a self-reported previous HIV-positive test FIGURE. Prevalence of human immunodeficiency virus among men who have sex with men,* by recruitment venue and age group — Bangkok, Thailand, 2003 and 2005



* Refers to men who have sex with men but who were not enrolled at venues where male sex workers or transgendered persons congregate.
† 95% confidence interval.

[§] p<0.01.

** p<0.05 by χ^2 test.

result.[§] Sex with women during the preceding 3 months was inversely associated with HIV infection (Table). In multivariate analysis, residing in Bangkok or Chiang Mai, older age, drug use, and refusal to disclose a previous HIV test result were significantly and independently associated with HIV infection.

Among MSW, recruitment from a park or street location, self-identification as homosexual or gay, receptive or both insertive and receptive anal intercourse, self-reported genital ulcer or discharge, and a self-reported previous HIV-positive test result were significantly associated with HIV infection in univariate analysis. Sex with women during the preceding 3 months was inversely associated with HIV infection. In multivariate analysis, recruitment from a park or street location, self-reported genital ulcer or discharge, and a self-reported previous HIV-positive test result were significantly and independently associated with HIV infection; sex with women during the preceding 3 months was inversely associated with HIV infection.

Among TG, older age, recruitment from a park or street location, lower education, history of selling sex, and a higher

[¶]p<0.001.

[§] Because nearly all Thai men are uncircumcised, circumcision was not evaluated as a possible risk factor for HIV infection.

TABLE. Prevalence of human immunodeficiency virus (HIV) infection among a sample* of men who have sex with men (MSM),[†] male sex workers (MSW), and transgendered persons (TG), by selected demographic and behavioral characteristics — Thailand, 2005

	MSM HIV prevalence Univariate							MS	w				т	G	
	HIV	′ preva	lence		Univariate	HI	/ preva	lence		Univariate	HIV	/ preva	lence		Univariate
Characteristic	No.	Sample	e (%)	OR§	(95% CI)¹	No.	Sample	e (%)	OR	(95% CI)	No. S	Sample	e (%)	OR	(95% CI)
Location Bangkok Chiang Mai Phuket	113 34 11	399 222 200	(28.3) (15.3) (5.5)	6.79 3.11	(3.56–12.95)** (1.53–6.32)** Referent	66 23 29	350 202 202	(18.9) (11.4) (14.4)	1.39 0.77	(0.86–2.23) (0.43–1.38) Referent	23 26 15	200 148 126	(11.5) (17.6) (11.9)	0.96 1.58	(0.48–1.92) (0.80–3.13) Referent
Age group (yrs) 15–22 23–28	33 68	316 280	(10.4) (24.3)	2.75	Referent (1.75-4.32)**	43 50	307 314	(14.0) (15.9)	1.16	Referent (0.75–1.81)	19 26	227 156	(8.4) (16.7)	2.19	Referent (1.17–4.11) ^{††}
<u>></u> 29	57	225	(25.3)	2.91	(1.82–4.65)**	25	133	(18.8)	1.42	(0.83–2.44)	19	91	(20.9)	2.89	(1.45–5.76)**
Recruitment venue Entertainment/ Sex work ^{§§} Sauna Park/Street [¶]	41 47 64	183 158 411	(22.4) (29.7) (15.6)	3.03 4.45 1.94	(1.22–7.51) (1.80–10.98) (0.80–4.66)	80 0 38	582 172	(13.7) (22.1)	1.78	Referent 	30 0 24	289 81	(10.4)	1.09 3.96	(0.51–2.31)
Elsewhere***	6	69	(8.7)		Referent	0	_			—	10	104	(9.6)		Referent
Education Primary or less Vocational University	11 93 54	60 457 304	(18.3) (20.4) (17.8)	1.04 1.18	(0.51–2.13) (0.82–1.72) Referent	28 83 7	196 520 38	(14.3) (16.0) (18.4)	0.74 0.84	(0.30–1.85) (0.36–1.97) Referent	5 54 5	21 375 78	(23.8) (14.4) (6.4)	4.56 2.46	(1.18–17.64) ^{†††} (0.95–6.36) Referent
Sexual identity Homosexual/Gay Bisexual Heterosexual	126 24 8	544 144 133	(23.2) (16.7) (6.0)	4.71 3.13	(2.24–9.89) (1.35–7.23) Referent	61 24 33	279 155 320	(21.9) (15.5) (10.3)	2.43 1.59	(1.54–3.85) (0.91–2.80) Referent	28 1 35	133 10 298	(16.9) (10.0) (11.7)	1.53 0.84	(0.89–2.61) (0.10–6.79) Referent
Usual anal sex role Insertive Receptive Both	38 49 65	288 255 210	(13.2) (19.2) (31.0)	1.57 2.95	Referent (0.99–2.48) (1.89–4.62)	44 29 36	384 131 163	(11.5) (22.1) (22.1)	2.20 2.19	Referent (1.31–3.69) (1.35–3.56)	2 47 10	9 390 45	(22.2) (12.1) (22.2)	2.09 2.09	(0.42–10.34) Referent (0.97–4.49)
No anal sex	6	68	(8.8)		—	9	76	(11.8)		_	5	30	(16.7)		_
Had sex with women during the preceding 3 months Yes	10	125	(8.0)	0.32	(0.16–0.63)	27	325	(8.3)	0.34	(0.21–0.53)**	1	3	(33.3)		
No Ever sold sex	148	696	(21.3)		Referent	91	429	(21.2)		Referent	63	471	(13.4)		Referent
Yes No	62 96	303 518	(20.5) (18.5)	1.13	(0.79–1.62) Referent	99 19	614 140	(16.1) (13.6)	1.22	(0.72–2.08) Referent	48 16	288 182	(16.7) (8.8)	2.08	(1.14–3.78) Referent
Number of intercourse partners during the preceding 3 months															
≤1 2–5 ≥6	74 44 40	377 248 196	(19.6) (17.7) (20.4)	0.88 1.05	Referent (0.68–1.62) (0.58–1.35)	24 30 64	158 184 412	(15.2) (16.3) (15.5)	1.09 1.03	Referent (0.62–1.71) (0.66–1.95)	19 15 30	176 139 159	(10.8) (10.8) (18.9)	1.00 1.92	Referent (0.49–2.05) (1.03–3.57)
Condom use during intercourse during the preceding 3 months Always	61	317	(19.2)	1.14	(0.74–1.74)	60	358	(16.8)	1.10	(0.72–1.66)	23	199	(11.6)	0.69	(0.39–1.24)
Not always No intercourse partners	45 52	260 244	(17.3) (21.3)	1.14	Referent	47 11	303 93	(15.5) (11.8)		Referent	31 10	195 80	(11.0) (15.9) (12.5)	0.03	Referent
Self-reported genital ulcer or discharge Ever Never	110 48	476 345	(23.1) (13.9)	1.86	(1.28–2.70) Referent	89 29	477 277	(18.7) (10.5)	1.96	(1.25–3.07) ^{††} Referent	42 22	321 153	(13.1) (14.4)	0.90	(0.51–1.56) Referent
Alcohol use during the preceding 3 months Yes No	130 28	671 150	(19.4) (18.7)	1.05	(0.67–1.65) Referent	110 8	700 54	(15.7) (14.8)	1.07	(0.49–2.33) Referent	50 14	384 90	(13.0) (15.6)	0.81	(0.43–1.55) Referent
Drug use ^{§§§} during lifetime Ever Never	85 73	374 447	(22.7) (16.3)	1.51	(1.06–2.14)** Referent	89 29	542 212	(16.4) (13.7)	1.24	(0.79–1.95) Referent	42 22	307 167	(13.7) (13.2)	1.05	(0.60–1.82) Referent
Drug use during the preceding 3 months Yes No	37 121	189 632	(19.6) (19.1)	1.03	(0.68–1.55) Referent	59 59	345 409	(17.1) (14.4)	1.22	(0.83–1.81) Referent	28 36	202 272	(13.9) (13.2)	1.06	(0.62–1.80) Referent
Surgery Penile-vaginal reconstructive surgery Cosmetic surgery Never had surgery											9 19 36	89 134 251	(10.1) (14.2) (14.3)	1.47 1.49	Referent (0.63–3.41) (0.69–3.23)

TABLE. (*Continued*) Prevalence of human immunodeficiency virus (HIV) infection among a sample* of men who have sex with men (MSM),[†] male sex workers (MSW), and transgendered persons (TG), by selected demographic and behavioral characteristics — Thailand, 2005

			MSI	N				MS	w				т	G	
	HI	V preval	ence		Univariate	н	V preval	ence	U	nivariate	HI	V preval	ence		Univariate
Characteristic	No.	Sample	(%)	OR§	(95% CI) ¹	No.	Sample	(%)	OR	(95% CI)	No.	Sample	(%)	OR	(95% CI)
Female hormone															
therapy															
Ever	—	—	—		_	_	—	—		—	50	413	(12.1)		Referent
Oral	_		_		_		_	_		_	17	107	(15.9)	1.83	(0.91-3.69)
Injection	_	—	_		_	_	_	_		_	14	103	(13.6)	1.52	(0.73 - 3.18)
Both	_	_	_		_	_	_	_		_	19	203	(9.4)		Referent
Never	_	_	—		_	—	_	_		_	11	53	(20.8)	1.90	(0.92–3.93)
Had HIV test															
Ever	76	356	(21.3)	1.27	(0.90-1.80)	77	453	(17.0)	1.30	(0.86-1.96)	37	221	(16.7)	1.68	(0.99-2.87)
Never	82	465	(17.6)		Referent	41	301	(13.6)	I	Referent	27	253	(10.7)		Referent
Result of HIV test															
Negative	51	298	(17.1)		Referent	47	323	(14.6)	1	Referent	26	179	(14.5)		Referent
Positive	8	16	(50.0)	4.84	(1.74–13.50)**	6	9	(66.7)	11.75	(2.84–48.59)**	1	1	`— ´		_
Would not disclose	17	42	(40.5)	3.29	(1.66–6.54)**	24	121	(19.8)	1.45	(0.84–2.50)	10	41	(24.4)	1.90	(0.83 - 4.33)
Never tested	82	465	(17.6)	1.04	(0.71–1.52)	41	301	(13.6)	0.93	(0.59–1.46)	27	253	(10.7)	0.70	(0.40-1.25)

 * N = 2,049.

[†] MSM refers to men who have sex with men but who were not enrolled at venues where male sex workers or transgendered persons congregate.

Odds ratio.
 Confidence interval.

** p<0.001 in multivariate generalized estimating equation logistic regression analysis, adjusting for clusters of venues and calendar dates. Only variables with bivariate p values of <0.05 were entered in the analysis. Statistical significance is defined as p<0.05.

^{††} p<0.01.

^{§§} In this venue-based assessment, group membership (MSM, MSW, or TG) was defined by the type of enrollment venue. MSM were enrolled from entertainment venues (e.g., bars and discos), MSW from sex-work venues (e.g., "go-go" bars [i.e., bars where sex workers can be solicited] and massage parlors), and TG from sex-work venues (e.g., "go-go" bars and cabaret show theaters). At sex-work venues, all personnel (e.g., waiters and dancers) were offered enrollment; clients were not enrolled.

MSM were enrolled from parks only, MSW were enrolled from parks and street locations, and TG were enrolled from street locations only.

**** Dormitories (MSM and TG) and beauty salons and barber shops (TG).

††† p<0.05.

588 Including noninjected drugs, "ecstasy" (methylenedioxymethamphetamine), methamphetamine, ketamine, cocaine, inhaled nitrates, and benzodiazepines.

number of sex partners during the preceding 3 months were significantly associated with HIV infection in univariate analysis. In multivariate analysis, older age, being recruited from a park or street location, and lower education were significantly and independently associated with HIV infection.

Reported by: F van Griensven, PhD, A Varangrat, MSc, W Wimonsate, MSc, JW Tappero, MD, C Sinthuwattanawibool, MSc, JM McNicholl, MD, PA Mock, MAppStat, Thailand Ministry of Public Health – U.S. Centers for Disease Control and Prevention Collaboration; T Siraprapasiri, MD, Dept of Disease Control, Thailand Ministry of Public Health, Nonthaburi; P Phanuphak, MD, AIDS Research Centre, Thai Red Cross Society; R Jommaroeng, MSc, Rainbow Sky Assoc of Thailand, Bangkok; S Visarutratana, PhD, Chiang Mai Provincial Health Office, Chiang Mai; T Netwong, MD, P Utokasenee, Phuket Patong Hospital, Patong, Thailand. RA Jenkins, PhD, G Mansergh, PhD, C Toledo, PhD, Div of HIV/AIDS Prevention, National Center for HIV, Viral Hepatitis, STDs, and Tuberculosis Prevention (proposed), CDC.

Editorial Note: Twenty years after Thailand's first AIDS case was reported in a young homosexual man (4), Thai MSM, MSW, and TG remain at high risk for HIV infection. HIV prevalence is especially high among MSM aged 15–22 years. Because these MSM have been sexually active for a brief period,

the HIV prevalence in this group suggests a high underlying HIV incidence.

The increase in HIV prevalence in Bangkok MSM cannot be explained by differences in the methodology of the two surveys; sampling, specimen collection, and testing methods were the same. Moreover, with the exception of the decreased age threshold (15 years in the 2005 survey versus 18 years in the 2003 survey), eligibility criteria also were identical. The mean age of participants in both surveys was the same (27 years). Sample size calculation determined that 399 MSM were enrolled for the study in Bangkok during 2005. Before the 2003 assessment, data on HIV prevalence among MSM were unavailable; thus, 1,121 MSM were enrolled to allow estimation of a wide range of possible prevalences with a 95% degree of confidence and to have sufficient cell sizes for detailed statistical analysis.

Risk factors for HIV infection in the assessment were similar to those previously identified (5). Sex with women was independently associated with a lower risk for HIV infection among MSW. This finding might be attributed, in part, to the fact that the majority of MSW (62.9%) in the survey identified themselves as nonhomosexual, with nearly all of these (84.4%) reporting that they did not engage in receptive anal intercourse, the practice associated with the highest risk for HIV infection (5). Another factor might be the low HIV prevalence among women in Thailand, making heterosexual acquisition of HIV less likely. In 2005, HIV prevalence among pregnant women attending public antenatal care facilities in Thailand was 1.0% (6). Injection-drug use was low in the study population, suggesting that among MSM, MSW, and TG in Thailand, HIV is predominantly transmitted sexually. Nevertheless, analysis of the 2005 data indicates that lifetime use of any noninjected drug (mostly smoked methamphetamine) was reported frequently by MSW (38.5%), TG (24.1%), and MSM (15.5%). The use of drugs, particularly those that are injected or enhance or prolong sexual pleasure, among MSM, MSW, and TG in Thailand needs further monitoring because drug use patterns might change over time.

The results of this analysis also indicate lack of awareness of current HIV status in the study population, particularly among those who were HIV positive. Of the 340 men who tested HIV positive in the 2005 survey, 274 (80.6%) reported that they were HIV negative or that they had never been tested for HIV infection. Of these 274 men, 57 (20.8%) received their first HIV-positive test result as part of this assessment. Overall, of 2,049 participants, 511 (24.9%) returned for their HIV test results, of whom 64 (12.5%) were HIV positive. All 64 men were referred for confirmatory EIA serum testing and HIV treatment and care, including immunologic evaluation (CD4 cell count) to determine eligibility for highly active antiretroviral therapy (HAART) and antimicrobial prophylaxis and treatment, according to Thai national guidelines (3). To decrease and prevent HIV risk behaviors (7), MSM, MSW, and TG in Thailand should be encouraged to get tested for HIV infection more frequently (8) so that they can take measures to protect themselves and their partners from HIV infection.

The findings in this report are subject to at least three limitations. First, the study population consisted of men who were present at venues where MSM, MSW, and TG congregate to socialize and find sex partners or clients. Men who do not attend these venues might have different HIV risk factors and HIV prevalence. Second, men with higher risk for HIV infection might have attended multiple venues and might have enrolled in the study more than once, thereby inflating HIV prevalence estimates. This possibility is unlikely, however, because data-collection periods were brief (approximately 2 weeks), and travel among venues is uncommon in Bangkok. Moreover, MSW and TG typically worked and lived at the venue where they enrolled, making their enrollment at another venue improbable. Finally, men who attend venues frequently might have a higher HIV prevalence and were more likely to be included in the assessment, thereby inflating HIV prevalence estimates. However, no association between venue attendance and HIV prevalence was determined; thus, the data were not weighted for frequency of attendance.

The high HIV prevalence among MSM, MSW, and TG in Thailand, as documented in this report, highlights the need for more effective behavioral and biomedical interventions to prevent the spread of HIV in these populations at high risk. Interventions should include programs to reduce sexual risk behavior, promotion of more frequent voluntary HIV counseling and testing, and improved services for diagnosis and treatment of sexually transmitted infections.

Acknowledgments

This report is based, in part, on contributions by S Naorat, MA, T Guadamuz, MHS, P Akarasewi, MD, C Kittinunvorakoon, PhD, P Wasinrapee, MSc, S Kurachit, MA, B Jumtee, N Tippanont, T Chemnasiri, W Thienkrua, Thailand Ministry of Public Health – U.S. Centers for Disease Control and Prevention Collaboration; S Thanprasertsuk, MD, P Sirivongrangson, MD, Dept of Disease Control, Thailand Ministry of Public Health, Nonthaburi; S Tantipaibulvut, A Jamrasrak, P Chuariyakul, AIDS Research Centre, Thai Red Cross Society; K Kanggarnrua, D Linjongrat, P Chanlearn, Rainbow Sky Assoc of Thailand, Bangkok, Thailand.

References

- 1. van Griensven F, Thanprasertsuk S, Jommaroeng R, et al. Evidence of a previously undocumented epidemic of HIV infection among men who have sex with men in Bangkok, Thailand. AIDS 2005;19:521–6.
- Mansergh G, Naorat S, Jommaroeng R, et al. Adaptation of venue-daytime sampling in southeast Asia to access men who have sex with men for HIV assessment in Bangkok. Field Methods 2006;18:135–52.
- Thailand Ministry of Public Health. Guidelines for the care and treatment of HIV/AIDS in children and adults in Thailand, 8th edition. Nonthaburi, Thailand: Division of AIDS, Department of Disease Control, Thailand Ministry of Public Health; 2004.
- 4. Wangroongsarb Y, Weniger BG, Wasi C, et al. Prevalence of LAV/HTLV III antibody in selected populations in Thailand. South East Asian J Trop Med Public Health 1985;16:517–20.
- 5. Caceres C, van Griensven GJP. Editorial review: the male homosexual transmission of the human immunodeficiency virus. AIDS 1994;8: 1051–61.
- Thailand Ministry of Public Health. HIV sero-surveillance in Thailand: result of the 23rd round, June 2005. Nonthaburi, Thailand: Thailand Ministry of Public Health; 2006.
- 7. CDC. Advancing HIV prevention: new strategies for a changing epidemic—United States, 2003. MMWR 2003;52:329–32.
- CDC. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men—five U.S. cities, June 2004–April 2005. MMWR 2005;54:597–601.

HIV Counseling, Testing, and Care of Tuberculosis Patients at Chest Clinics — Guyana, 2005–2006

Tuberculosis (TB) is a leading cause of morbidity and mortality among persons living with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) (1). During 2004, Guyana had an estimated TB incidence rate of 140 per 100,000 population (1), the fourth highest rate in the Americas (after Haiti, Bolivia, and Peru); Guyana also had an estimated adult HIV prevalence of 2.5% (2), and 20% of TB patients were reported to be infected with HIV (3). In 2000, the Guyana Ministry of Health (MOH) began providing HIV counseling, testing, and referrals to HIV/AIDS programs at its six public chest clinics.* At the end of 2005, chest clinics also began providing co-trimoxazole preventive therapy (CPT) to HIV-infected TB patients as a measure against common opportunistic infections. During February-June 2006, an international team[†] assessed the extent to which MOH chest clinics in Guyana had implemented these interventions during July 2005-June 2006. This report summarizes the results of that assessment, which determined that, among 253 TB patients sampled, 174 (69%) initially did not know their HIV-infection status; 127 (73%) of those patients were offered HIV counseling and testing, and 115 (91%) accepted and were tested for HIV. Of the 115 who were tested, 11 (10%) were determined to be HIV infected; overall, 68 (35%) of the 194 patients whose HIV-infection status was known were HIV infected (i.e., 11 who were tested at the chest clinics plus 57 with preexisting knowledge of their HIV status). These results indicate both a high rate of HIV infection among TB patients in Guyana and the ability of chest clinics to provide HIV-related interventions in resourcelimited settings.

In Guyana, approximately 90% of all reported TB cases are diagnosed and patients treated at the six MOH chest clinics (3). These clinics provide on-site rapid HIV testing and, with the exception of one facility, are located on the same campus or within 1 kilometer of MOH's HIV clinics. Chest clinics currently do not prescribe antiretroviral therapy (ART) to TB patients who are HIV infected, although this is planned for the future. When possible, however, chest clinics employ clinicians trained in both TB and HIV patient care. All patients starting TB treatment at the chest clinics during July– December 2005 whose health-care records (e.g., patient medical records, treatment cards, or registers and logs at chest and HIV clinics) were located were included in the evaluation. Data on patient demographics, diagnosis, laboratory tests, and treatment were collected. TB disease was defined using World Health Organization (WHO) laboratory or clinical case definitions (4). HIV-related care was defined as receipt of at least one of the following: symptom screening for HIV-related complications, CD4+ T-lymphocyte cell count monitoring, or provision of CPT or ART.

During the 6-month evaluation period, 380 patients were registered as starting TB treatment at the six chest clinics. Of these, health-care records for 253 (67%) patients were located and available for review. Similar to most resource-limited settings, Guyana's MOH chest clinics do not use electronic medical records or formal record-tracking systems, hindering attempts to locate patient records. The median age of the TB patients was 38 years (range: 9 months–82 years). Seventy-nine (31%) of the 253 patients reported knowing their HIV-infection status before starting TB treatment and were not retested for HIV (Table). Of the remaining 174 patients with unknown HIV status before diagnosis of TB, 127 (73%) were offered HIV counseling and testing, and 115 (91%) of the 127 agreed to be tested. Eleven (10%) of those tested were HIV infected. The 47 (27%) patients with unknown HIV status who were not offered HIV counseling and testing were less likely to have had a secondary education (prevalence odds ratio [POR]: 4.6, 95% confidence interval [CI] = 1.5–15.0, p<0.01) and more likely to be aged >44 years (POR: 11.0, CI = 2.4–99.0, p<0.01) than those offered HIV testing. Among the 194 patients for whom HIV status was determined, 68 (35%) were HIV infected (57 who self-reported their HIV serostatus before starting TB treatment and 11 who had been tested for HIV infection at the chest clinics). Documentation of HIV-related care was available for 54 (79%) of the 68 HIV-infected patients. Among these 54 patients, 38 (70%) had a recent CD4+ T-lymphocyte cell count recorded, 43 (80%) had been prescribed CPT, and 18 (33%) had been prescribed ART (Table). Patients not documented as receiving ART either were not referred to or did not comply with referral to an HIV clinic, did not meet national criteria for ART initiation, refused ART initiation, or had HIV clinic medical records that were unavailable for review (i.e., their MOH HIV clinic records were not located or they received HIV-related care at a private facility). Rates of CPT use did not differ significantly by patient sex, race/ethnicity, age group, or education level.

Reported by: S Persaud, MBBS, J Mohanlall, MBBS, Ministry of Health, Guyana. M Bateganya, MD, C Anude, MD, Guyana office of the Francois-Xavier Bagnoud Center/Univ of Medicine and Dentistry

^{*}The public health-care facilities in Guyana responsible for diagnosing TB infection in patients and managing their disease.

[†]Team members included Guyana MOH, the Guyana office of the Francois-Xavier Bagnoud Center/University of Medicine and Dentistry of New Jersey, the Canadian Society for International Health, and CDC.

TABLE. Number and percentage of tuberculosis (TB) patients using Ministry of Health chest clinics, by demographic and human immunodeficiency virus (HIV)–related care* chacteristics and HIV-infection status — Guyana, 2005–2006

	All TB pa	atients		-infected patients [†]
Characteristic	No.	(%)	No.	(%)
Sex				
Male	179	(71)	41	(60)
Female	74	(29)	27	(40)
Total	253	(100)	68	(100)
Age group (yrs)				
0-14	5	(2)	1	(2)
15–24	30	(12)	5	(6)
25–34	68	(27)	25	(37)
35–44	63	(25)	25	(37)
45–54	52	(21)	11	(16)
55–64	21	(8)	1	(2)
>64	12	(4)	0	
Unknown	2	(1)	0	—
Race/Ethnicity [§]				
East Indian	61	(24)	8	(12)
Afro-Guyanese	124	(49)	42	(62)
Mixed	50	(19)	16	(23)
Amerindian	15	(6)	2	(3)
Chinese	1	(1)	0	
Unknown	2	(1)	0	
Education level				
Less than secondary	76	(30)	24	(35)
Secondary or higher	94	(37)	25	(37)
Not documented	83	(33)	19	(28)
Knew HIV status before				<i>i</i> =
TB diagnosis ¹	79	(31)	57	(84)
If HIV status unknown,				
offered HIV testing	127/174	(73)	—	—
HIV tested	115/127	(91)		
HIV infected	_	_	11/115	(10)
Not HIV infected	_	_	104/115	(90)
Total no. of persons				
for whom HIV status	10.1	()		
was established	194	(77)	_	—
HIV infected	68	(35)	_	—
HIV non-infected	126	(65)	_	—
Received HIV-related care				(24)
No	_	_	14	(21)
Yes	_	_	54	(79)
Prescribed CPT** Prescribed ART	_	_	43 18	(80)
	_	_		(33)
Median CD4 count (range)		_	101	(1–1,024)

* Defined as receipt of at least one of the following: HIV-focused symptom and behavioral screening, CD4+ T-lymphocyte cell count monitoring, or prescription of co-trimoxazole preventive therapy (CPT) or antiretroviral therapy (ART).

[†] Received diagnoses of HIV infection before TB diagnoses or were determined to be HIV infected after testing at a chest clinic.

§ Race/ethnicity classifications are those used by the Guyana Ministry of Health.

Patient knowledge of HIV status as documented by clinician or healthcare records. No additional verification of self-reported HIV status was made.

** Health-care providers reported adverse reactions in two of the 43 patients who received CPT.

of New Jersey. C La Fleur, MD, Canadian Society for International Health. TH Holtz, MD, CD Wells, MD, Div of Tuberculosis Elimination; A DuBois, MD, S Filler, MD, Div of Global AIDS, National Center for HIV, Viral Hepatitis, STDs, and Tuberculosis Prevention (proposed); S Chideya, MD, EIS Officer, CDC.

Editorial Note: According to WHO recommendations, 1) HIV testing and counseling should be offered to all TB patients in settings where the HIV prevalence among TB patients exceeds 5%; 2) TB control programs should establish a referral linkage with HIV/AIDS programs to provide a continuum of care and support for persons living with HIV/AIDS who are receiving or who have completed their TB treatment; and 3) TB and HIV/AIDS programs should establish a system to provide CPT to eligible persons living with HIV/AIDS who have active TB (5). The assessment described in this report demonstrated that of the TB patients using Guyana's MOH chest clinics for whom HIV status was determined, 35% were HIV infected, and 79% of these patients received varying types of HIV-related care; in addition, 73% of those who did not know their HIV status upon arrival at the chest clinic were offered HIV counseling and testing. These findings support the usefulness of chest clinics in the initiation and maintenance of HIV-related interventions in resourcelimited settings. The chest clinics provided HIV counseling and testing to 73% of eligible TB patients, which compares well with published rates for other countries where HIV prevalence among TB patients exceeds 5% (1,6-8). Comparable reports regarding provision of HIV-related care by chest clinics in other countries have not been published.

Although these clinics had the capacity to provide HIV counseling and testing and HIV-related care, 27% of TB patients met national Guyana guidelines for receipt of HIV counseling and testing (i.e., had unknown HIV infection status) but were not documented as receiving these interventions. Discrepant rates of HIV counseling and testing by demographic characteristics (i.e., age and education level) were noted. Further study might be considered to determine what factors (e.g., communication or cultural) might have resulted in older TB patients and those with less education being less likely to be offered HIV counseling and testing. Strengthening the observance of national guidelines regarding HIV counseling and testing (in addition to CPT use and referrals to HIV/AIDS programs) to include all persons, regardless of demographics, is critical. In addition, because one third of eligible patient records could not be located during this assessment, improving current medical record filing and tracking systems likely would improve patient management.

The findings in this report are subject to at least five limitations. First, data were missing from patient records at all six chest clinics, and 33% of patient records were not available; whether the HIV-related characteristics of these patients differed significantly from the sampled group is unknown. Second, 27% of patients with unknown HIV status at the time of TB diagnosis were not offered HIV counseling and testing; whether the proportion of HIV infection in this patient group differed significantly from those who were tested is unknown. Third, patient reports of receiving HIV-related health care from private providers were not verified. Fourth, self-reports of HIV status could not be confirmed for some patients (i.e., those not visiting MOH HIV clinics). Finally, MOH chest clinics did not begin providing CPT to HIV-infected TB patients until the end of 2005. HIV-infected patients who completed most or all of their TB-related care before chest clinic distribution of CPT might have lower rates of use.

Because HIV-related care is available to patients without cost in Guyana, adoption of routine diagnostic HIV testing for all persons visiting chest clinics (i.e., "opt-out" testing) should be considered, including for persons unable to provide documentation of their HIV status. Routine testing could increase the detection of HIV infections and enable more HIVinfected TB patients to receive HIV-related care. In addition, training should be provided regularly to chest clinic staff members to underscore the importance of observing national TB and HIV guidelines. Further integrating TB and HIV control measures (e.g., by including in Guyana's National HIV Registry those HIV-infected patients who received their diagnoses at chest clinics and who receive HIV-related care at non-MOH facilities) could provide additional safeguards for patient follow-up and appropriate health care.

References

- 1. World Health Organization. Global health atlas. Geneva, Switzerland: World Health Organization; 2006. Available at http://www.who.int/ globalatlas/default.asp.
- 2. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2004 report on the global AIDS epidemic: Guyana. Geneva, Switzerland: UNAIDS; 2005.
- Ministry of Health, Guyana. Annual report, 2004. Georgetown, Guyana: Guyana Tuberculosis Control Program, Department of Disease Control, Ministry of Health; 2005.
- World Health Organization. Treatment of tuberculosis, guidelines for national programmes. Geneva, Switzerland: World Health Organization; 2003:24.
- World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva, Switzerland: World Health Organization; 2004:4–10.
- DeRiemer, K, Soares, EC, Dias SM, Cavalcante SC. HIV testing among tuberculosis patients in the era of antiretroviral therapy: a populationbased study in Brazil. Int J Tuberc Lung Dis 2000;4:519–27.
- Chimzizi ŘB, Harries AD, Manda E, Khonyongwa A, Salaniponi FM. Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation. Int J Tuberc Lung Dis 2004;8:938–44.
- van der Werf MJ, Yegorova OB, Chechulin Y, Hasker E, Veen J, Turchenko LV. HIV testing practices of TB patients after introduction of a new testing policy in Kiev City, Ukraine. Int J Tuberc Lung Dis 2005;9:733–9.

Trends in HIV-Related Risk Behaviors Among High School Students — United States, 1991–2005

Young persons who engage in unprotected sexual intercourse or use injection drugs are at increased risk for human immunodeficiency virus (HIV) infection. To examine changes in HIV-related risk behavior among high school students in the United States during 1991-2005, CDC analyzed data from eight national Youth Risk Behavior Surveys (YRBS) conducted during that period. This report summarizes the results of that analysis, which indicated that, during 1991-2005, the percentage of U.S. high school students engaging in HIV-related sexual risk behaviors decreased. During 1995-2005, the percentage of U.S. high school students who ever injected drugs remained less than 4%. However, many students still engage in HIV-related risk behaviors. Measures aimed at changing these behaviors should be strengthened to decrease the incidence and prevalence of HIV/AIDS among young persons and meet the national 2010 objective for adolescent sexual behavior (objective 25-11) (1).

The biennial national YRBS, a component of CDC's Youth Risk Behavior Surveillance System, used independent, threestage cluster samples for the 1991–2005 surveys to obtain cross-sectional data representative of public and private school students in grades 9–12 in all 50 states and the District of Columbia. Sample sizes ranged from 10,904 to 16,296. School response rates ranged from 70% to 81%, and student response rates ranged from 83% to 90%; overall response rates for the surveys ranged from 60% to 70%.

For each cross-sectional national survey, students completed anonymous, self-administered questionnaires that included identically worded questions about sexual experience, number of sex partners, current sexual activity, condom use, and injection-drug use.* Sexual experience was defined as ever having had sexual intercourse. Multiple sex partners was defined as having four or more sex partners during the person's lifetime. Current sexual activity was defined as having sexual intercourse during the 3 months preceding the survey. Condom use was defined as use of a condom during last sexual intercourse among currently sexually active students. Begin-

^{*} The YRBS questions were as follows: "Have you ever had sexual intercourse?" "During your life, with how many people have you had sexual intercourse?" "During the past 3 months, with how many people have you had sexual intercourse;" "The last time you had sexual intercourse, did you or your partner use a condom?" and "During your life, how many times have you used a needle to inject any illegal drug into your body?" The wording of the question on injection-drug use changed substantially after the 1993 survey, so 1991 and 1993 data are not included in this report.

ning with the 1995 survey, injection-drug use was defined as ever having used a needle to inject any illegal drug into the body. Race/ethnicity data are presented only for non-Hispanic black, non-Hispanic white, and Hispanic students (who might be of any race); the numbers of students from other racial/ ethnic groups were too small for meaningful analysis.

Data were weighted to provide national estimates, and the statistical software used for data analysis accounted for the complex sample design. Temporal changes were analyzed using logistic regression analyses, which controlled for sex, race/ethnicity, and grade and simultaneously assessed linear and quadratic time effects (2). Quadratic trends indicate a statistically significant but nonlinear trend in the data over time (e.g., a leveling off or significant change in direction). Trends that include significant linear and quadratic components demonstrate nonlinear variation in addition to an over-all increase or decrease over time.

During 1991–2005, the prevalence of sexual experience decreased 13% from 54.1% to 46.8% among high school students. Logistic regression analyses indicated a significant linear decrease overall and among female, male, 9th-grade, 10th-grade, 11th-grade, 12th-grade, black, and white students (Table). A significant quadratic trend also was detected among black students and 11th-grade students. Among black students, this trend indicated that the prevalence of sexual experience declined during 1991–2001 and then leveled off through 2005. Among 11th-grade students, the prevalence of sexual experience declined during 1991–1997 and then leveled off through 2005. Prevalence of sexual experience did not decrease significantly among Hispanic students.

During 1991–2005, the prevalence of multiple sex partners decreased 24% from 18.7% to 14.3%. A significant linear decrease was detected overall and among female, male, 9th-grade, 10th-grade, 11th-grade, 12th-grade, black, and white

TABLE. Percentage of high school students who reported HIV*-related risk behaviors, by sex, grade, race/ethnicity, and survey year — United States, Youth Risk Behavior Survey, 1991, 1993, 1995, 1997, 1999, 2001, 2003, and 2005

	Survey haracteristic year		ad sexual course	sex	ur or more partners g lifetime	interco	l sexual urse during ng 3 months	duri	condom ng last ntercourse [§]		sed illegal on drugs ^୩
Characteristic	year	%	(95% CI [†])	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
Total	1991 1993	54.1 53.0	(±3.5) (±2.7)	18.7 18.7	(±2.1) (±2.0)	37.4 37.5	(±3.1) (±2.1)	46.2 52.8	(±3.3) (±2.7)		
	1995	53.1	(±4.5)	17.8	(±2.6)	37.9	(±3.4)	54.4	(±3.5)	2.1	(±0.4)
	1997 1999	48.4 49.9	(±3.1) (±3.7)	16.0 16.2	(±1.4) (±2.6)	34.8 36.3	(±2.2) (±3.5)	56.8 58.0	(±1.6) (±4.2)	2.1 1.8	(±0.5) (±0.4)
	2001	45.6	(±3.7) (±2.3)	14.2	(±2.0) (±1.2)	33.4	(±3.3) (±2.0)	57.9	(±2.2)	2.3	(±0.4)
	2003	46.7	(±2.6)	14.4	(±1.6)	34.3	(±2.1)	63.0	(±2.5)	3.2	(±1.2)
	2005	46.8	(±3.3)**	14.3	(±1.5)**	33.9	(±2.5)**	62.8	(±2.1)**	2.1	(±0.3)
Sex											
Female	1991	50.8	(±4.0)	13.8	(±1.8)	38.2	(±3.4)	38.0	(±4.3)		_
	1993	50.2	(±2.5)	15.0	(±1.9)	37.5	(±1.8)	46.0	(±2.8)		_
	1995	52.1	(±5.0)	14.4	(±3.5)	40.4	(±4.2)	48.6	(±5.2)	1.0	(±0.5)
	1997	47.7	(±3.7)	14.1	(±2.0)	36.5	(±2.7)	50.8	(±3.0)	1.5	(±0.8)
	1999	47.7	(±4.1)	13.1	(±2.2)	36.3	(±4.1)	50.7	(±5.8)	0.7	(±0.3)
	2001	42.9	(±2.8)	11.4	(±1.5)	33.4	(±2.5)	51.3	(±3.4)	1.6	(±0.4)
	2003	45.3	(±2.6)	11.2	(±1.4)	34.6	(±2.1)	57.4	(±3.1)	2.5	(±1.3)
	2005	45.7	(±3.6)**	12.0	(±1.6)**	34.6	(±3.0)	55.9	(±2.8)**	1.1	(±0.4)
Male	1991	57.4	(±4.1)	23.4	(±3.0)	36.8	(±3.4)	54.5	(±3.8)		_
	1993	55.6	(±3.5)	22.3	(±2.7)	37.5	(±3.0)	59.2	(±3.8)		_
	1995	54.0	(±4.7)	20.9	(±2.6)	35.5	(±3.5)	60.5	(±4.3)	3.0	(±0.6)
	1997	48.8	(±3.4)	17.6	(±1.5)	33.4	(±2.6)	62.5	(±2.8)	2.6	(±0.6)
	1999	52.2	(±4.0)	19.3	(±3.6)	36.2	(±3.9)	65.5	(±4.3)	2.8	(±0.8)
	2001	48.5	(±2.7)	17.2	(±1.6)	33.4	(±2.3)	65.1	(±2.7)	3.1	(±0.4)
	2003	48.0	(±3.3)	17.5	(±2.2)	33.8	(±2.5)	68.8	(±2.6)	3.8	(±1.3)
	2005	47.9	(±3.4)**	16.5	(±1.8)**	33.3	(±2.6)	70.0	(±3.1)**	3.0	(±0.5)
Grade											
9	1991	39.0	(±5.0)	12.5	(±2.9)	22.4	(±3.9)	53.3	(±6.2)		_
	1993	37.7	(±4.2)	10.9	(±2.0)	24.8	(±3.2)	61.6	(±5.7)		_
	1995	36.9	(±5.9)	12.9	(±3.0)	23.6	(±4.0)	62.9	(±5.5)	2.8	(±1.1)
	1997	38.0	(±3.8)	12.2	(±2.5)	24.2	(±3.3)	58.8	(±5.6)	3.0	(±1.8)
	1999	38.6	(±6.1)	11.8	(±2.3)	26.6	(±5.7)	66.6	(±7.8)	1.6	(±0.6)
	2001	34.4	(±3.6)	9.6	(±1.6)	22.7	(±3.1)	67.5	(±3.3)	2.5	(±0.9)
	2003	32.8	(±3.8)	10.4	(±2.0)	21.2	(±2.5)	69.0	(± 6.4)	3.2	(±1.8)
	2005	34.3	(±3.5)**	9.4	(±1.5)**	21.9	(±2.4)	74.5	(±5.1)**	2.4	(±0.7)

MMWR

and survey year —	Survey	Ever ha	nd sexual course	Had for sex p	ur or more partners g lifetime	Had intercou	sexual urse during og 3 months	Used duri	condom ng last ntercourse [§]	Ever us	sed illegal on drugs¶
Characteristic	year	%	(95% CI [†])	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
10	1991 1993 1995	48.2 46.1 48.0	(±5.7) (±3.6) (±5.1)	15.1 15.9 15.6	(± 2.8) (± 2.0) (± 2.0)	33.2 30.1 33.7	(±4.6) (±3.0) (±3.1)	46.3 54.7 59.7	(± 4.7) (± 4.5) (± 4.6)	2.2	(±1.4)
	1997 1999 2001 2003	42.5 46.8 40.8 44.1	(± 4.3) (± 5.6) (± 3.0) (± 2.8)	13.8 15.6 12.6 12.6	(± 2.7) (± 5.0) (± 1.8) (± 2.4)	29.2 33.0 29.7 30.6	(±2.9) (±5.2) (±2.9) (±2.5)	58.9 62.6 60.1 69.0	(± 3.6) (± 6.1) (± 4.5) (± 4.7)	2.5 1.2 2.6 3.2	(± 1.3) (± 0.5) (± 0.7) (± 1.6)
11	2005 1991 1993	42.8 62.4 57.5	(±3.9)** (±3.2) (±3.5)	11.5 22.1 19.9	(±2.0)** (±3.6) (±3.1)	29.2 43.3 40.0	(±2.9) (±3.6) (±3.6)	65.3 48.7 55.3	$(\pm 3.9)^{**}$ (± 5.8) (± 3.0)	2.3	(±0.6)
	1995 1997 1999 2001	58.6 49.7 52.5 51.9	(±5.0) (±5.2) (±3.8) (±2.9)	19.0 16.7 17.3 15.2	(± 3.7) (± 2.9) (± 4.1) (± 1.5)	42.4 37.8 37.5 38.1	(± 4.4) (± 4.8) (± 3.4) (± 2.6)	52.3 60.1 59.2 58.9	(± 6.2) (± 5.2) (± 4.8) (± 4.0)	1.7 1.6 2.0 1.9	(±0.6) (±0.7) (±1.2) (±0.6)
12	2003 2005 1991	53.2 51.4 66.7	(±4.3) (±5.2)** ^{††} (±4.4)	16.0 16.2 25.0	(± 2.6) $(\pm 2.4)^{**}$ (± 4.0)	41.1 39.4 50.6	(±3.9) (±4.3) (±4.5)	60.8 61.7 41.4	(±4.8) (±3.8)** (±3.6)	2.8 1.7	(±1.3) (±0.5)
	1993 1995 1997 1999	68.3 66.4 60.9 64.9	(± 4.6) (± 4.0) (± 6.5) (± 4.9)	27.0 22.9 20.6 20.6	(± 3.6) (± 3.5) (± 3.5) (± 2.8)	53.0 49.7 46.0 50.6	(± 3.9) (± 3.9) (± 5.0) (± 5.1)	46.5 49.5 52.4 47.9	(± 0.0) (± 4.0) (± 4.4) (± 3.5) (± 5.7)	1.6 1.5 2.3	(±0.9) (±0.8) (±0.9)
Race/Ethnicity ^{§§}	2001 2003 2005	60.5 61.6 63.1	(±4.0) (±3.8) (±4.1)**	21.6 20.3 21.4	(±2.4) (±2.0) (±2.8)**	47.9 48.9 49.4	(±4.0) (±3.5) (±3.8)	49.3 57.4 55.4	(±3.1) (±3.7) (±3.5)**	2.1 3.0 1.7	(±0.6) (±1.6) (±0.5)
Black, non-Hispanic	1991 1993 1995 1997 1999 2001 2003 2005	81.4 79.7 73.4 72.6 71.2 60.8 67.3 67.6	(± 3.2) (± 3.2) (± 4.5) (± 2.8) (± 8.2) (± 6.6) (± 3.3) $(\pm 3.1)^{**\dagger\dagger}$	43.1 42.7 35.6 38.5 34.4 26.6 28.8 28.2	(± 3.5) (± 3.8) (± 4.4) (± 3.6) (± 10.3) (± 3.7) (± 2.5) $(\pm 2.6)^{**}$	59.3 59.1 54.2 53.6 53.0 45.6 49.0 47.4	(± 3.8) (± 4.4) (± 4.7) (± 3.2) (± 8.9) (± 5.4) (± 2.9) $(\pm 2.6)^{**}$	48.0 56.5 66.1 64.0 70.0 67.1 72.8 68.9	(± 3.8) (± 3.8) (± 4.8) (± 2.8) (± 5.4) (± 3.5) (± 3.7) $(\pm 3.6)^{**\dagger\dagger}$	1.1 1.0 0.9 1.6 2.4 1.7	(±0.6) (±0.7) (±0.5) (±0.7) (±1.1) (±0.9)
Hispanic	1991 1993 1995 1997 1999 2001 2003 2005	53.1 56.0 57.6 52.2 54.1 48.4 51.4 51.0	(± 3.5) (± 4.1) (± 8.6) (± 3.6) (± 4.8) (± 4.5) (± 3.2) (± 3.2) (± 4.3)	16.8 18.6 17.6 15.5 16.6 14.9 15.7 15.9	(± 2.6) (± 3.1) (± 3.7) (± 2.4) (± 3.6) (± 1.7) (± 2.2) (± 2.4)	37.0 39.4 39.3 35.4 36.3 35.9 37.1 35.0	(± 3.6) (± 3.7) (± 7.1) (± 3.9) (± 4.0) (± 3.2) (± 2.8) (± 3.9)	37.4 46.1 44.4 48.3 55.2 53.5 57.4 57.7	(± 6.2) (± 4.4) (± 11.1) (± 5.6) (± 6.8) (± 5.1)	2.2 2.2 1.8 2.5 3.9 3.0	(±0.9) (±0.6) (±0.8) (±0.7)
White, non-Hispanic	1991 1993 1995 1997 1999 2001 2003 2005	50.0 48.4 48.9 43.6 45.1 43.2 41.8 43.0	(± 3.2) (± 2.8) (± 5.0) (± 4.2) (± 3.9) (± 2.5) (± 2.7) $(\pm 4.1)^{**}$	14.7 14.3 14.2 11.6 12.4 12.0 10.8 11.4	(± 1.8) (± 2.1) (± 2.4) (± 1.5) (± 2.1) (± 1.4) (± 1.5) $(\pm 1.8)^{**}$	33.9 34.0 34.8 32.0 33.0 31.3 30.8 32.0	(± 2.8) (± 2.1) (± 3.9) (± 3.1) (± 3.3) (± 2.2) (± 2.0) (± 3.3)	46.5 52.3 52.5 55.8 55.0 56.8 62.5 62.6	(± 4.6) (± 3.9) (± 4.0) (± 2.0) (± 5.1) (± 3.0) (± 3.1) $(\pm 2.5)^{**}$	2.0 1.8 1.6 2.4 2.5 1.9	$\begin{array}{c} (\pm 0.6) \\ (\pm 0.5) \\ (\pm 0.4) \\ (\pm 0.5) \\ (\pm 1.3) \\ (\pm 0.4) \end{array}$

TABLE. (*Continued*) Percentage of high school students who reported HIV*-related risk behaviors, by sex, grade, race/ethnicity, and survey year — United States, Youth Risk Behavior Survey, 1991, 1993, 1995, 1997, 1999, 2001, 2003, and 2005

* Human immunodeficiency virus.

[†] Confidence interval.

§ Among students who had sexual intercourse during the 3 months preceding the survey.

¹ Ever used a needle to inject any illegal drug into the body. The wording of the question on injection-drug use changed substantially after the 1993 survey, so 1991 and 1993 data are not included in this report.

** Significant linear effect (p<0.05).

⁺⁺ Significant quadratic effect (p<0.05).

§§ Numbers of students in racial/ethnic groups other than non-Hispanic black, Hispanic, or non-Hispanic white were too small for meaningful analysis. Hispanic students might be of any race. students (Table). Prevalence of multiple sex partners did not decrease significantly among Hispanic students.

During 1991–2005, the prevalence of current sexual activity decreased 9% from 37.4% to 33.9%. A significant linear decrease was detected overall and among black students (Table), but the prevalence of current sexual activity did not decrease significantly among any other subgroups of students. Among currently sexually active students, the prevalence of condom use increased 36% from 46.2% to 62.8%. A significant linear increase in condom use was detected overall and among all subgroups of students. Among black students, a significant quadratic trend also was detected, indicating that the prevalence of condom use among currently sexually active black students increased during 1991–1999 and then leveled off through 2005.

During 1995–2005, the prevalence of injection-drug use remained below 4%. No significant change was observed overall or among any subgroups of students.

Reported by: N Brener, PhD, L Kann, PhD, R Lowry, MD, H Wechsler, EdD, L Romero, DrPH, Div of Adolescent and School Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

Editorial Note: The overall decrease in HIV-related sexual risk behaviors among high school students discussed in this report corresponds to a simultaneous decrease in gonorrhea (3), pregnancy (4), and birth rates (5) among adolescents. These improvements in health outcomes likely resulted from the combined contributions of parents and families, schools, youth-serving community organizations, health-care providers, the media, government agencies, and the youths themselves and improved availability of effective interventions that address HIV-related knowledge, skills, and behaviors and their determinants (e.g., peer norms and media influences). However, additional measures are needed to eliminate disparities among subgroups; for example, black students are more likely than white and Hispanic students to report HIV-related sexual risk behaviors (6), and Hispanic students have not experienced decreases in the prevalence of sexual experience, having had multiple sex partners, or current sexual activity.

The findings in this report are subject to at least two limitations. First, these data apply only to youths who attend school and therefore are not representative of all persons in this age group. In 2001, among persons aged 16–17 years, approximately 5% were not enrolled in a high school program and had not completed high school (7). Second, the extent of underreporting or overreporting of behaviors cannot be determined, although the survey questions demonstrated good test-retest reliability (8). A national health objective for 2010 (objective 25-11) is to increase the proportion of adolescents in grades 9-12 who abstain from sexual intercourse or use condoms if they are currently sexually active (1). Increased measures are needed to meet this 2010 objective and reduce the incidence and prevalence of HIV/AIDS among young persons.

References

- 1. US Department of Health and Human Services. Healthy people 2010, 2nd ed. With understanding and improving health and objectives for improving health. Washington, DC: US Department of Health and Human Services; 2000.
- 2. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5th ed. Boston, MA: Houghton Mifflin; 2003.
- 3. CDC. Sexually transmitted disease surveillance, 2003. Atlanta, GA: US Department of Health and Human Services; 2004.
- 4. Ventura SJ, Abma JC, Mosher WD, Henshaw S. Estimated pregnancy rates for the United States, 1990–2000: an update. Nat Vital Stat Rep 2004;52:1–12.
- 5. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: final data for 2003. Nat Vital Stat Rep 2005;54:1–25.
- Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance— United States, 2005. In: Surveillance Summaries, June 9, 2006. MMWR 2006;55(No. SS-5).
- Kaufman P, Alt MN, Chapman C. Dropout rates in the United States: 2001. Washington, DC: US Department of Education, National Center for Education Statistics; 2004. Publication No. 2005-046.
- Brener ND, Kann L, McManus T, Kinchen SA, Sundberg EC, Ross JG. Reliability of the 1999 Youth Risk Behavior Survey questionnaire. J Adolesc Health 2002;31:336–42.

Vibrio parahaemolyticus Infections Associated with Consumption of Raw Shellfish — Three States, 2006


On August 7, this report was posted as an MMWR Dispatch on the MMWR website (http://www.cdc.gov/mmwr).

During May 20–July 31, 2006, New York City, New York state, Oregon, and Washington health departments reported a total of 177 cases of *Vibrio parahaemolyticus* infection, of which 122 have been associated with 17 clusters. A cluster has been defined as a group of two or more ill persons who were linked to the same shellfish source (e.g., shared a meal at the same restaurant or obtained shellfish from the same seafood market). Certain clusters were associated with restaurants, certain clusters with seafood markets, and certain clusters with recreational harvesting. Three patients were hospitalized; no fatalities have been reported. No demographic (e.g., age, sex, or race) or medical history (e.g., predisposing conditions) information is yet available regarding affected persons.

A confirmed case of *V. parahaemolyticus* infection is defined as an infection confirmed by isolation of the organism from a patient's stool. A probable case is defined as gastroenteritis in a person who can be epidemiologically linked to a confirmed case. Of the 177 *V. parahaemolyticus* cases reported, 72 are confirmed and 105 are probable: New York City (two confirmed, 74 probable), New York state (seven confirmed), Oregon (eight confirmed, eight probable), and Washington (55 confirmed, 23 probable). This incidence of infection is much higher than expected; during May, June, and July 2000– 2004, these jurisdictions reported an annual average of 16 laboratory-confirmed *V. parahaemolyticus* cases to CDC (Figure). The number of confirmed cases in this report (72) is more than the average number reported during May, June, and July during 2000–2004, in the entire United States (Figure).

Subtyping of *V. parahaemolyticus* isolates has indicated that 18 of 23 isolates tested are serotype O4:K12, which is unrelated to the pandemic strain that was first identified in Asia in 1996 and later emerged in the United States in 1998 (*1,2*). Traceback investigations have linked contaminated oysters and contaminated clams to harvest areas in Washington and British Columbia, Canada; shellfish from these sources were distributed to seafood markets and restaurants nationwide.

FIGURE. Number of *Vibrio parahaemolyticus* cases* from New York,[†] Oregon, and Washington,[§] by month, compared with 5-year average numbers of confirmed cases nationwide and from New York, Oregon, and Washington during 2000–2004,[¶] by month



* A confirmed case of V. parahaemolyticus infection is defined as an infection that is confirmed by isolation of the organism from a patient's stool. A probable case is defined as gasteroenteritis in a person who can be epi-, demiologically linked to a confirmed case.

¹Data from 2005 are not yet available.

Ongoing investigations are being conducted by state and local health departments and regional Food and Drug Administration (FDA) shellfish-control offices to identify additional sources of infection. Additional infections likely have been undetected, underreported, or both.

V. parahaemolyticus infection causes acute, self-limited gastroenteritis typically characterized by diarrhea, abdominal cramps, nausea, vomiting, fever, and chills of 1–3 days duration, with onset usually within 24 hours after eating contaminated food. Cases are most commonly reported during warmer months and are often associated with eating raw or undercooked shellfish or other cooked foods that have been cross-contaminated by raw shellfish.

Previous local *V. parahaemolyticus* outbreaks have coincided with large increases in sporadic cases nationally, suggesting that identified clusters are most often manifestations of a wider increase in illness (1). Studies suggest that approximately 20 *V. parahaemolyticus* illnesses exist for each laboratory-confirmed case reported to CDC (3,4), underscoring the need for enhanced national surveillance and control measures.

Shellfish harvest areas in the United States and Canada that were previously implicated in V. parahaemolyticus outbreaks are routinely monitored by state shellfish-control agencies to control transmission of these illnesses. Despite acceptable V. parahaemolyticus levels detected by routine testing of shellfish in these areas, as of July 31, 2006, eight shellfish harvest areas in Washington had been closed to harvesting because their oysters were associated with this Vibrio illness outbreak. Oysters from these areas have been recalled by Washington state shellfish-control authorities. Shellfish bed monitoring is an important element of food-safety control but is not sufficient to prevent illnesses caused by Vibrio organisms. Because vibrios multiply rapidly, even low levels of V. parahaemolyticus in harvested products can rapidly increase to infectious levels if not rapidly refrigerated after harvest and maintained at proper temperatures during transport, processing, and storage (i.e., $<50^{\circ}F$ [$<10^{\circ}C$]).

Medical providers should request stool specimens from patients with acute gastroenteritis and a history of recent shellfish consumption. The microbiology laboratory analyzing the sample should be notified that *Vibrio* illness, or vibriosis, is suspected so that appropriate methods (ideally, culture in the selective medium thiosulfate-citrate-bile salts-sucrose [TCBS] agar) can be used to isolate the organisms. *Vibrio* species grow readily in blood agar, but primary isolation of the organisms from stool samples is problematic because extensive screening is required to differentiate vibrios from other enteric organisms (5).

¹ Includes health jurisdictions of New York state and New York City.

⁸As of July 31, 2006.

Vibrio species infections should be reported to the appropriate health jurisdiction. Although infection with *V. parahaemolyticus* is not currently a nationally notifiable disease (as is cholera, the disease caused by cholerigenic strains of *Vibrio cholerae*),* CDC has conducted voluntary case surveillance for laboratory-confirmed noncholera *Vibrio* species infection since 1988. In June 2006, the Council of State and Territorial Epidemiologists recommended that all *Vibrio* species infections be classified as nationally notifiable diseases. The current outbreak underscores the benefits of coordinated national surveillance.

Consumption of raw or undercooked shellfish is a recurrent source of human illness, including sporadic infections and widespread outbreaks. In recent years, the most commonly reported pathogens associated with these infections have been V. parahaemolyticus, Vibrio vulnificus, and norovirus, but outbreaks of hepatitis A and cholera also have been reported. To decrease the risk for V. parahaemolyticus infection, shellfish should be thoroughly cooked to kill illness-causing pathogens.[†] In two of the New York City clusters in this report, vibriosis was associated with cooked seafood (e.g., cooked lobster, scallops, crab, or shrimp) that was eaten in a restaurant, suggesting that the food might have been cross-contaminated by raw shellfish after cooking. Some commercially available oysters have been treated after harvest to reduce the levels of Vibrio bacteria. Improved surveillance for V. parahaemolyticus, in addition to increased use of postharvest treatment to decrease Vibrio species levels, and careful postharvest temperature control of shellfish during transport, processing, and storage are critical to limiting V. parahaemolyticus infections.

Reported by: S Balter, H Hanson, L Kornstein, L Lee, V Reddy, S Sahl, F Stavinsky, New York City Dept of Health and Mental Hygiene; M Fage, G Johnson, New York State Dept of Health. J Bancroft, W Keene, Oregon Dept of Human Svcs. J Koepsell, M Williams, Public Health Seattle and King County; K MacDonald, N Napolilli, J Hofmann, Washington State Dept of Health. C Bopp, M Lynch, K Moore, J Painter, N Puhr, P Yu, Div of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed), CDC.

References

- 1. Daniels NA, Ray B, Easton A, et al. Emergence of a new *Vibrio parahaemolyticus* serotype in raw oysters: a prevention quandary. JAMA 2000;284:1541–5.
- Matsumoto C, Okuda J, Ishibashi M, et al. Pandemic spread of an O3:K6 clone of *Vibrio parahaemolyticus* and emergence of related strains evidenced by arbitrarily primed PCR and *toxRS* sequence analyses. J Clin Microbiol 2000;38:578–85.
- Mead PS, Slutsker L, Dietz V. Food-related illness and death in the United States. Emerg Infect Dis 1999;5:607–25.
- CDC. Cholera and other *Vibrio* illness surveillance system. Atlanta, GA: US Department of Health and Human Services, CDC. Available at http:// www.cdc.gov/foodborneoutbreaks/outbreak_data.htm.
- Farmer JJ, Janda JM, Birkhead K. *Vibrio* [Chapter 46]. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Washington, DC: ASM Press; 2003.

Notice to Readers

Epidemic Intelligence Service Application Deadline — September 15, 2006

The Epidemic Intelligence Service (EIS) is a 2-year, postgraduate program of service and on-the-job training for health professionals interested in the practice of epidemiology. Each year, EIS provides approximately 90 persons from around the world opportunities to gain hands-on experience in epidemiology at CDC or state or local health departments. EIS officers, often called CDC's "disease detectives," have gone on to occupy leadership positions at CDC and other public health agencies. However, the experience also is useful for health professionals who are seeking to gain a population health perspective.


Persons with a strong interest in applied epidemiology who meet at least one of the following qualifications may apply to EIS:

- Physicians with ≥ 1 year of clinical training.
- Persons with a PhD, DrPH, or other doctoral degree in epidemiology, biostatistics, the social or behavioral sciences, natural sciences, or the nutrition sciences.
- Dentists, physician assistants, and nurses with an MPH or equivalent degree.
- Veterinarians with an MPH or equivalent degree or relevant public health experience.

Applications are now being accepted for the July 2007– June 2009 EIS program. Deadline for submitting application materials is September 15, 2006. Application information and EIS program details are available at http://www.cdc.gov/eis; by telephone, 404-498-6110; or via e-mail, eisepo@cdc.gov.

^{*} The Nationally Notifiable Diseases Surveillance System is a public health surveillance system that collects data on cases of certain diseases. The decision to make a disease nationally notifiable is based on its public health importance (e.g., number of cases or severity of the disease) and its preventability. The current list of nationally notifiable diseases is available at http://www.cdc.gov/ epo/dphsi/phs/infdis.htm.

[†] Cooking guidelines vary for each type of shellfish and are available from FDA at http://www.cfsan.fda.gov/-lrd/seafsafe.html or by telephone (888-723-3366).



SOURCE: National Health Interview Survey, 2001–2003. Available at http://www.cdc.gov/nchs/nhis.htm.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending August 5, 2006 (31st Week)*

	Current	Cum	5-year weekly	Total o	cases rep	orted for	previou	s years	
Disease	week	2006	average [†]	2005	2004	2003	2002	2001	States reporting cases during current week (No.)
Anthrax	_	1		_	_	_	2	23	
Botulism:							_		
foodborne	_	3	1	19	16	20	28	39	
infant	1	48	1	89	87	76	69	97	UT (1)
other (wound & unspecified)	3	33	1	33	30	33	21	19	CA (3)
Brucellosis	_	59	3	122	114	104	125	136	
Chancroid	1	22	Ō	17	30	54	67	38	TX (1)
Cholera	_	4	0	8	5	2	2	3	
Cyclosporiasis§	2	54	6	734	171	75	156	147	SC (1), FL (1)
Diphtheria	_	_	_	_	_	1	1	2	
Domestic arboviral diseases ^{§,1} :									
California serogroup	_	4	6	78	112	108	164	128	
eastern equine	_	_	1	21	6	14	10	9	
Powassan	_	_	0	1	1	_	1	N	
St. Louis	_	1	2	10	12	41	28	79	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis [§] :									
human granulocytic	11	154	20	789	537	362	511	261	NY (2), MN (9)
human monocytic	7	148	11	518	338	321	216	142	NY (1), NC (3), TN (2), TX (1)
human (other & unspecified)	_	41	2	122	59	44	23	6	(.), (.), (.)
Haemophilus influenzae,**			-		00		20	Ū	
invasive disease (age <5 yrs):									
serotype b	_	4	0	9	19	32	34	_	
nonserotype b	1	50	2	135	135	117	144	_	MI (1)
unknown serotype	7	122	3	214	177	227	153	_	ND (1), MD (1), TN (1), AL (2), AR (2)
Hansen disease [§]	_	35	2	87	105	95	96	79	
Hantavirus pulmonary syndrome§	_	20	0	29	24	26	19	8	
Hemolytic uremic syndrome, postdiarrheal§	4	98	6	221	200	178	216	202	CT (1), GA (1), TN (2)
Hepatitis C viral, acute	9	448	34	755	713	1,102	1,835	3,976	NY (1), MI (1), KS (1), NC (1), FL (1), CO (1),
	Ũ		0.			.,	.,000	0,010	WA (1), CA (2)
HIV infection, pediatric (age <13 yrs) ^{§,††}	_	52	5	380	436	504	420	543	(.),(_)
Influenza-associated pediatric mortality §. §§. 11	_	41	0	49	_	N	Ň	N	
Listeriosis	10	308	20	887	753	696	665	613	NY (1), MI (1), MD (2), GA (1), FL (1), WA (1), CA (3)
Measles	***	25	1	66	37	56	44	116	
Meningococcal disease, ^{†††} invasive:									
A, Č, Y, & W-135	_	136	4	297	_	_	_	_	
serogroup B	_	89	2	157	_	_	_	_	
other serogroup	_	12	1	27	_	_	_	_	
Mumps	18	5,482	6	314	258	231	270	266	NY (4), OH (1), ND (1), KS (6), VA (1), FL (1),
		,							TN (1), ID (1), CA (2)
Plague	_	5	0	8	3	1	2	2	
Poliomyelitis, paralytic	_	_	_	1	_	_	_	_	
Psittacosis§	_	10	0	19	12	12	18	25	
Q fever [§]	4	82	1	137	70	71	61	26	FL (1), TX (2), CO (1)
Rabies, human	_	1	0	2	7	2	3	1	
Rubella	_	5	0	10	10	7	18	23	
Rubella, congenital syndrome	_	1	_	1	_	1	1	3	
SARS-CoV ^{§,§§}		_	_	_	_	8	N	N	
Smallpox [§]	—	_	—	_	—	_	—	_	
Streptococcal toxic-shock syndrome§	1	66	1	125	132	161	118	77	NY (1)
Streptococcus pneumoniae,§									
invasive disease (age <5 yrs)	8	666	8	1,257	1,162	845	513	498	NY (1), OH (1), IN (1), MD (1), AR (1), TX (2), CO (1)
Syphilis, congenital (age <1 yr)	3	134	8	361	353	413	412	441	LA (1), AZ (2)
Tetanus	—	14	1	26	34	20	25	37	
Toxic-shock syndrome (other than streptococc	al)§ 2	55	2	96	95	133	109	127	CA (2)
Trichinellosis	_	9	0	19	5	6	14	22	
Tularemia [§]	1	45	4	151	134	129	90	129	NE (1)
Typhoid fever	6	132	8	322	322	356	321	368	OH (1), MD (1), FL (2), NM (1), CA (1)
Vancomycin-intermediate Staphylococcus aur	reus§ —	2	_	2	_	Ν	Ν	N	
		_		3	1	N	N	N	
Vancomycin-resistant Staphylococcus aureus [§] Yellow fever									

-: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.

* Incidence data for reporting years 2005 and 2006 are provisional, whereas data for 2001, 2002, 2003, and 2004 are finalized.

[†] Calculated by summing the incidence counts for the current week, the two weeks preceding the current week, and the two weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.

§ Not notifiable in all states.

Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNET Surveillance).

** Data for *H. influenzae* (all ages, all serotypes) are available in Table II.

^{††} Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, STD and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Data for HIV/AIDS are available in Table IV quarterly.

§§ Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases.

11 A total of 37 cases were reported for the 2005-06 flu season (October 2, 2005 [week 40]–May 20, 2006 [week 20]).

*** No measles cases were reported for the current week.

ttt Data for meningococcal disease (all serogroups and unknown serogroups) are available in Table II.

			Chlamyd	lia†			Coccid	lioidomy	cosis			Cryp	otosporio	liosis	
			vious	-				ious					vious	_	_
Reporting area	Current week	<u>52 v</u> Med	veeks Max	Cum 2006	Cum 2005	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	52 v Med	veeks Max	Cum 2006	Cum 2005
United States	11,538	18,442	34,984	528,518	565,898	117	146	1,643	5,019	2,283	50	62	844	1,529	1,575
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island Vermont [§]	421 79 60 239 — 33 10	625 170 41 280 35 66 19	1,550 1,214 74 432 64 95 43	18,720 5,536 1,216 8,320 1,022 1,959 667	19,218 5,917 1,269 8,387 1,103 1,971 571	N N 	0 0 0 0 0 0	0 0 0 0 0 0	N N N	N N N	3 - - - 3	4 0 1 1 0 0	35 14 3 15 3 6 5	97 12 14 35 12 4 20	95 9 15 41 13 2 15
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1,213 81 576 556	2,172 366 499 571 728	3,696 500 1,727 1,456 1,075	56,887 10,196 14,038 9,719 22,934	69,715 11,579 13,930 22,517 21,689	N N N N	0 0 0 0 0	0 0 0 0		N N N N	14 — 9 — 5	10 0 3 1 5	597 8 561 15 21	216 7 69 18 122	203 13 54 48 88
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1,486 488 132 260 561 45	3,122 975 389 582 746 399	12,578 1,536 552 9,888 1,449 531	87,013 28,907 9,472 18,157 19,086 11,391	95,052 29,864 11,694 15,629 25,877 11,988	2 N 2 N	0 0 0 0 0	3 0 3 1 0	29 — N 25 4 N	5 N 5 N	4 — 3 1 —	14 1 1 2 5 4	162 16 13 7 109 38	330 32 34 58 116 90	382 56 21 46 94 165
W.N. Central lowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	691 109 195 274 103 10	1,141 151 233 433 92 33 52	1,456 225 269 340 562 176 58 117	34,406 4,780 4,760 6,450 12,983 2,978 968 1,487	34,863 4,094 4,276 7,339 13,473 3,118 944 1,619	N N N N N N	0 0 0 0 0 0 0	12 0 12 0 1 0 0	N N N N N N N	4 N 3 1 N N	7 2 1 	10 1 3 2 1 0 0	52 11 5 22 37 4 4 4	273 41 32 98 51 22 6 23	242 70 16 50 83 10 13
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	2,666 88 31 754 2 316 565 362 548	3,383 69 57 902 618 355 557 278 425 58	4,920 92 103 1,089 2,142 492 1,772 1,306 840 226	104,394 2,122 1,541 28,258 15,809 10,569 19,409 10,843 13,907 1,936	106,724 1,938 2,219 25,861 18,480 11,015 20,115 11,510 14,060 1,526	X X X Z Z Z	0 0 0 0 0 0 0 0 0	1 0 0 1 0 0 0 0 0	2 N N 2 N N N N	1 N N 1 N N N	17 	14 0 6 3 0 1 0 1	54 2 3 28 9 4 10 4 8 3	368 1 9 155 101 10 44 22 22 4	282 5 130 66 13 31 10 23 4
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	1,174 	1,226 369 1 378 490	1,850 754 273 609 614	37,728 11,613 167 11,107 14,841	36,029 8,894 	N N N	0 0 0 0	0 0 0 0	N N N	N N N	1 — — 1	2 1 0 1	8 5 19 1 4	56 32 6 18	32 14 — 18
W.S. Central Arkansas Louisiana Oklahoma Texas [§]	1,331 143 100 135 953	2,086 158 277 226 1,358	3,605 340 761 2,159 1,773	63,088 4,466 9,278 6,704 42,640	67,839 5,051 11,938 6,411 44,439	N N	0 0 0 0	1 0 1 0	 	N N N N	2 2 —	3 0 1 2	30 2 21 3 19	78 10 1 22 45	61 2 4 29 26
Mountain Arizona Colorado Idaho [§] Montana Nevada [§] New Mexico [§] Utah Wyoming	716 504 — 4 84 124	1,055 359 180 52 42 83 172 93 26	1,839 642 482 168 195 432 338 136 55	28,528 10,677 3,113 1,773 1,464 2,078 5,833 2,810 780	37,612 13,166 8,793 1,395 1,363 4,350 5,282 2,606 657	39 39 N N 	112 108 0 0 1 0 1 0	452 448 0 0 4 2 3 2	3,483 3,417 N N 21 8 35 2	1,448 1,383 N N 43 13 7 2	2 2 — — —	2 0 1 0 0 0 0 0	9 2 3 2 4 1 3 3 3	68 11 19 7 12 3 6 6 4	75 7 23 8 12 9 8 6 2
Pacific Alaska California Hawaii Oregon [§] Washington	1,840 94 1,398 348	3,290 84 2,547 105 172 354	5,079 152 4,231 135 315 604	97,754 2,492 76,292 3,126 5,229 10,615	98,846 2,450 76,812 3,249 5,219 11,116	76 — 76 N N N	40 0 40 0 0	1,179 0 1,179 0 0 0	1,505 1,505 	825 — 825 N N N	 	3 0 0 1 0	52 2 14 1 20 38	43 3 1 39	203 — 123 1 49 30
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U 	0 0 18 0 1	46 0 37 117 5	U U —	U U 464 	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U N	0 0 0 0	0 0 0 0	U U N	U U N

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005

Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting years 2005 and 2006 are provisional. * Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

·				G	onorrhe	a		Hae		s influen es, all sei	<i>zae</i> , invas rotypes	sive			
	0		vious	0	0	0		/ious	0	0	0		vious	0	0
Reporting area	Current week	Med	eeks Max	Cum 2006	Cum 2005	Current week	Med	veeks Max	Cum 2006	Cum 2005	Current week	Med	veeks Max	Cum 2006	Cum 2005
United States	212	304	1,029	8,245	10,004	3,834	6,305	14,072	180,488	190,893	30	37	141	1,213	1,465
New England	21	25	75	655	885	73	105	288	3,255	3,609	5	2	19	98	106
Connecticut Maine [†]	16 4	0 2	37 12	156 73	197 111	18 1	41 2	241 6	1,293 72	1,585 78	4	0 0	9 4	27 12	31 7
Massachusetts New Hampshire	1	10 0	34 3	287 10	385 41	35	47 4	87 9	1,440 124	1,532 98	1	1 0	6 1	46 3	52 5
Rhode Island	_	0	25	50	57	18	7	19	286	283	_	Ō	7	2	7
Vermont [†]	_	3	9	79	94	1	1	4	40	33	_	0	2	8	4
Mid. Atlantic New Jersey	34 3	49 8	254 18	1,303 206	1,809 244	307 16	587 105	1,014 150	14,898 2,693	19,486 3,325	4	7 2	30 4	216 35	275 51
New York (Upstate)	24	23 7	227 32	617 100	604 501	139	123 149	455 402	3,610 2,346	3,850 5,871	2	2 0	27 4	84 2	78 50
New York City Pennsylvania	7	15	29	380	460	152	210	393	2,340 6,249	6,440	2	3	8	95	96
E.N. Central	28	50	110	1,225	1,762	566	1,273	7,047	34,569	37,818	5	5	14	170	264
Illinois Indiana	N	10 0	32 0	215 N	429 N	170 58	384 152	567 228	10,866 3,880	11,638 4,710	2	1	6 7	32 50	87 48
Michigan Ohio	3 25	13 16	29 34	338 417	425 385	111 216	233 381	5,880 661	7,336 8.671	6,034 12,136	1 2	0 1	3 6	16 50	13 85
Wisconsin		10	40	255	523	11	130	172	3,816	3,300		0	4	22	31
W.N. Central Iowa	4	33 5	260 14	1,003 133	1,113 144	218 10	363 32	461 54	10,719 968	10,923 901	1	2 0	15 0	72	76
Kansas	1	3	9	98	110	44	47	124	1,334	1,516	_	0	3	12	8
Minnesota Missouri	_	3 10	238 32	415 269	487 235	2 124	62 189	103 251	1,606 5,784	2,026 5,487	_	0 0	9 7	35 18	32 25
Nebraska [†]	1	2	6	49	69	37	22	56	755	715		0	2	4	10
North Dakota South Dakota	2	1	7 7	7 32	5 63	1	2 6	7 13	58 214	54 224	1	0 0	3 0	3	1
S. Atlantic	52	49	95	1,264	1,506	1,128	1,479	2,334	45,095	45,480	8	10	26	345	355
Delaware District of Columbia	_	1 1	4 5	18 40	32 23	33 23	25 36	44 66	870 963	477 1,178	_	0 0	1 1	1 2	5
Florida Georgia	28 18	18 11	39 26	559 243	531 413	368 2	429 294	549 1,014	13,397 7,102	11,580 8,353	4	3 2	9 12	116 59	87 76
Maryland [†]	4	4	10	100	106	119	129	231	3,995	4,072	3	1	5	43	47
North Carolina South Carolina [†]	N	0 1	0 7	N 57	N 73	354 136	279 128	766 748	9,712 4,893	9,414 5,122	1	0 1	9 3	41 25	59 23
Virginia† West Virginia	2	9 0	50 6	233 14	308 20	93	132 16	288 42	3,665 498	4,886 398	—	1 0	8 4	44 14	38 20
E.S. Central	7	8	34	257	20	442	508	698	15,255	14,333	3	2	4 6	70	71
Alabama [†]	5	4 0	23 0	135 N	97 N	50	178	308 96	5,342 75	5,182	2	0	4	20	15
Kentucky Mississippi	N	0	0	_	_	155	1 140	221	4,157	4,223	_	0	1	3	_
Tennessee [†]	2	4	12	122	117	237	182	279	5,681	4,928	1	1	4	47	56
W.S. Central Arkansas	10 5	5 2	31 6	119 53	147 45	586 69	861 81	1,430 186	27,057 2,375	27,429 2,596	2 2	1 0	15 2	42 7	84 7
Louisiana Oklahoma	5	0 2	4 24	5 61	28 74	96 31	165 83	354 764	5,648 2,485	6,578 2,609	_	0 1	2 14	1 34	31 43
Texas [†]	Ň	0	0	N	N	390	524	723	16,549	15,646	_	0	1	_	3
Mountain Arizona	26	29 3	57 36	752 80	749 87	140 97	217 85	552 201	6,034 2,494	8,047 2,961	1	4	8 7	130 59	155 79
Colorado	13	9	33	240	256	_	43	90	971	1,879	_	1	4	35	32
Idaho† Montana	5	3 2	11 7	91 39	76 24	_	3 3	10 20	100 113	55 82	_	0 0	1 0	3	4
Nevada† New Mexico†	_	1	6 6	34 27	55 43	1 25	24 30	194 64	698 1,092	1,687 952	_	0 0	1 4	17	13 16
Utah	8	7	19	229	195	17	17	24	495	394	_	0	4	14	7
Wyoming	_	0	3	12	13	_	2	6	71	37		0	2	2	4
Pacific Alaska	30 1	60 1	202 7	1,667 25	1,819 58	374 14	809 10	964 23	23,606 319	23,768 342	1	2 0	20 19	70 7	79 5
California Hawaii	20	43 1	105 3	1,214 30	1,327 38	242	660 19	831 36	19,344 560	19,818 579	_	0 0	9 1	15 11	32 8
Oregon [†]	5	7	21	217	215	_	28	58	807	921	1	1	6	35	34
Washington	4	8	90	181	181	118	73	142	2,576	2,108	_	0	4	2	
American Samoa C.N.M.I.	U U	0 0	0 0	U U	U U	U U	0 0	2 0	U U	U U	U U	0 0	0 0	U U	U U
Guam Puerto Rico	_	0 0	3 20	_	8	_	1 0	15 12	_	64	_	0 0	2 0	_	2
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005 (31st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting years 2005 and 2006 are provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

	Vol	. 55 /	′ No.	31
--	-----	--------	-------	----

(31st Week)*	,										-		-	,	
			A	Нера	titis (viral,	acute), by ty	/pe	В				Le	gionello	sis	
	Current		/ious /eeks	Cum	Cum	Current	Previ	ous eeks	Cum	Cum	Current		vious	Cum	Cum
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	week	Med	<u>veeks</u> Max	2006	2005
United States	35	73	245	1,854	2,230	28	84	597	2,197	3,080	39	41	126	1,017	985
New England	3	5	22	109	248	—	2	9	37	85	—	2	12	52	51
Connecticut Maine [†]	2 1	1 0	3 2	23 7	30 1	_	0 0	3 2	12	29 7	_	0 0	8 1	17 3	15 3
Massachusetts New Hampshire	_	2 0	14 7	50 16	149 58	_	1 0	5 2	14 7	28 17	_	1 0	6 1	19 1	22 6
Rhode Island Vermont [†]	_	0	4 2	6 7	5 5	_	0	2 1	4	1 3	_	0	10 3	9 3	3
Mid. Atlantic	2	8	24	159	377	6	8	55	208	408	23	15	38	338	342
New Jersey New York (Upstate)	2	2 1	9 14	46 48	71 59	4	3 1	10 43	65 39	155 36	 15	1 5	8 29	39 144	70 78
New York City Pennsylvania	_	1 1	10 6	28 37	185 62	2	1 3	5 9	14 90	82 135	8	0	9 17	9 146	63 131
E.N. Central	1	6	15	148	197	1	8	24	194	348	3	9	25	203	180
Illinois Indiana	_	1 0	11 5	27 17	60 11	_	0 0	6 17	7 28	101 19	1	1 0	5 6	14 14	24 12
Michigan	1	2 1	8 4	52 39	66 33	1	3 2	7	83 70	114 87	2	2 4	6 19	51 105	53 74
Ohio Wisconsin	_	1	4 5	13	27	_	2	4	6	27	_	4	5	105	17
W.N. Central Iowa	1	2 0	30 2	85 5	54 13	_	4 0	22 3	96 9	159 16	_	1 0	11 1	25 2	43 3
Kansas	_	0	5	22	11	_	0	2	7	19	_	0	1	1	2
Minnesota Missouri	1	0 1	29 4	9 31	3 23	_	0 3	13 7	10 64	15 86	_	0 0	10 3	14	11 17
Nebraska† North Dakota	_	0 0	3 2	11	4	_	0 0	1 0	6	19	_	0 0	2 1	4	2 1
South Dakota		0	3	7	_	_	0	1	_	4		0	6	4	7
S. Atlantic Delaware	14	11 0	34 2	294 9	361 5	8	23 1	66 4	668 22	865 19	8	8 0	19 2	220 4	217 12
District of Columbia Florida	7	0 4	2 18	2 116	2 127	6	0 8	2 19	5 247	8 300	5	0 3	2 8	9 90	3 58
Georgia Maryland [†]	6	1	6	38 32	79 31	2	3	8 10	97 95	133 93	- 1	0	4 6	9 46	19 61
North Carolina	1	0	20	54	42	_	0	23	92	98	—	0	5	20	17
South Carolina† Virginia†	_	0 1	3 11	10 29	22 50	_	2 1	7 18	43 27	100 90	_	0 1	1 7	2 34	10 29
West Virginia E.S. Central	1	0 1	3	4	3 139		0 5	18 16	40 160	24 174	2 1	0 1	3 7	6	8
Alabama [†]		0	13 9	45 9	17	1	2	7	74	50	_	Ó	1	36 7	33 9
Kentucky Mississippi	_	0 0	2 1	4	13	_	0 0	3 3	9	36	_	0 0	4 1	1	2
Tennesseet	1	1	7	32	109	1	2	12	77	88	1	1	7	28	22
W.S. Central Arkansas	_	7 0	77 9	117 30	240 9	_	13 1	315 4	352 24	331 42	_	1 0	32 3	30 1	19 4
Louisiana Oklahoma	_	0 0	4 2	1 4	43 4	_	0	3 17	6 19	50 29	_	0 0	1 3	1	3
Texas [†]	—	5	73	82	184	—	11	295	303	210	—	0	26	28	12
Mountain Arizona	2 1	6 2	18 16	160 91	182 95	4	6 4	39 23	155 86	332 211	3 1	2 0	7 3	55 20	58 12
Colorado Idaho†	1	1 0	4 2	25 8	21 18	_2	1 0	5 2	23 7	35 7	1	0 0	2 2	6 6	15 3
Montana Nevada [†]	_	0 0	2	6	7	_	0 0	7 4		3	_	0 0	1 2	3 3	4
New Mexico [†]	_	0	3	6 11	10 16	_	0	3	5	33 13	_	0	1	2	12 2
Utah Wyoming	_	0 0	2 1	11 2	14 1	_2	0 0	5 1	21	28 2	1	0 0	2 1	15	7 3
Pacific	11	19	163	737	432	8	10	61	327	378	1	2	9	58	42
Alaska California	9	0 15	1 162	672	3 359	1 6	0 7	1 41	3 254	7 254	1	0 2	1 9	58	41
Hawaii Oregon†	2	0 0	2 5	8 30	17 25	- 1	0 1	1 6	4 38	4 65	N	0	1 0	N	1 N
Washington	_	1	13	27	28	—	0	18	28	48	—	Ō	0	—	—
American Samoa C.N.M.I.	U U	0 0	0 0	U U	1 U	U U	0 0	0 0	U U	U	U U	0 0	0 0	U U	U U
Guam Puerto Rico	_	0	0 3		2		0	0 5	_	18	_	0	0	_	
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005 (31st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting years 2005 and 2006 are provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(31st Week)*			1					M . L			
		Pre	Lyme dise vious	ease			Prev	Malaria	1		
	Current		veeks	Cum	Cum	Current	52 w		Cum	Cum	
Reporting area	week	Med	Max	2006	2005	week	Med	Max	2006	2005	
United States	423	248	2,153	7,448	12,160	23	24	125	642	776	
New England Connecticut	72 69	37 8	780 753	1,207 942	2,164 256	_	1 0	12 10	39 10	34	
Maine [†]	3	2	26	52	159	—	0	1	3	3	
Massachusetts New Hampshire	_	2 5	163 31	32 155	1,623 96	_	0 0	3 3	17 8	24 4	
Rhode Island Vermont [†]	_	0 1	12 6	 26	11 19	_	0 0	8 1	1	2 1	
Mid. Atlantic	294	151	1,176	4,452	7,033	3	4	13	83	220	
New Jersey	6	26	163	1,047	2,630	1	1	4	28	56	
New York (Upstate) New York City	217	76 1	1,150 23	1,863 7	1,535 254	_	1 1	11 8	20 14	26 114	
Pennsylvania	71	40	271	1,535	2,614	2	1	3	21	24	
E.N. Central Illinois	3	13 0	73 6	511	1,307 101	_	2 1	8 5	63 20	87 47	
Indiana Miabigan	1 2	0 1	4 7	10 24	19 21	_	0 0	3 2	7 12	3 17	
Michigan Ohio		1	5	18	30	_	0	3	18	14	
Wisconsin	_	10	56	459	1,136	_	0	3	6	6	
W.N. Central Iowa	14	11 1	98 6	227 33	267 64	1	0 0	32 1	29 1	30 4	
Kansas Minnesota	 14	0 6	2 96	3 173	2 191	1	0 0	2 30	5 14	3 11	
Missouri	_	0	3	10	8	_	0	2	4	12	
Nebraska† North Dakota	_	0 0	2 3	7	_	_	0 0	2 1	3 1	_	
South Dakota	—	0	1	1	2	—	0	1	1	_	
S. Atlantic Delaware	25	30 8	124 26	846 284	1,256 444	11	6 0	15 1	196 5	172 3	
District of Columbia	2	0 1	7	20	7	4	0	2	3	6	
Florida Georgia	2	0	5 1	23	15 4	3	1	6 6	36 55	28 36	
Maryland [†] North Carolina	20	15 0	87 5	407 16	639 30	3 1	1 0	5 8	42 14	62 17	
South Carolina [†]	1	0 3	3 22	6 85	8 105	—	0	2 9	7	4 15	
Virginia† West Virginia	_	0	44	5	4	_	0	2	2	1	
E.S. Central	—	0	4	6	14	—	0	2	15	11	
Alabama† Kentucky	_	0 0	1 2	3	_	_	0 0	2 2	9	3	
Mississippi Tennessee [†]	_	0 0	0 4	3	 14	_	0 0	1 1	3 3	8	
W.S. Central	_	0	5	8	53	2	2	31	44	59	
Arkansas Louisiana	_	0 0	1 0	_	3 3	_	0 0	2 1	1	3 2	
Oklahoma	—	0	0	_	—	2	0	6	6	3	
Texas [†]	2	0 0	5 4	8 11	47 12	_	1	29 9	37 31	51 34	
Mountain Arizona	—	0	4	3	2	_	0	9	11	6	
Colorado Idaho†	1	0 0	1 1	2 1	1	_	0 0	2 0	9	19	
Montana Nevada [†]	_	0	0	_	3	—	0	1	1 1	2	
New Mexico [†]	_	0	1	_	2	_	Ō	1	1	2	
Utah Wyoming	1	0 0	1 0	5	1 3	_	0 0	2 1	8	4 1	
Pacific	13	4	22	180	54	6	4	13	142	129	
Alaska California	 13	0 3	1 21	2 172	3 31	4	0 3	4 10	18 96	3 93	
Hawaii	Ν	0	0	N	N	—	0	2	3	13	
Oregon [†] Washington	_	0 0	2 3	4 2	16 4	2	0 0	2 5	7 18	7 13	
American Samoa	U	0	0	U	U	U	0	0	U	U	
C.N.M.I. Guam	U	0 0	0 0	U	U	<u> </u>	0 0	0 0	<u> </u>	U	
Puerto Rico U.S. Virgin Islands	N	0	0	N	N	_	0	1 0	_	_	
		U	U				U	U	_		

Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting years 2005 and 2006 are provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(31st week)"				Mening	gococcal d	isease, inva	sive								
			All serog	roups			Sero	group u	nknown				Pertus	sis	
	•		vious		0		Previ						/ious	0	
Reporting area	Current week	Med	veeks Max	Cum 2006	Cum 2005	Current week	52 we Med	Max	Cum 2006	Cum 2005	Current week	Med	veeks Max	Cum 2006	Cum 2005
United States	4	20	83	681	821	4	13	56	444	496	146	289	2,876	7,399	12,666
New England	2	1	3	33	54	2	0	2	25	19	3	29	83	740	752
Connecticut Maine [†]	1	0 0	2 1	9 3	11 2	1	0	2 1	3 3	1 2	1	1	5 5	28 25	43 22
Massachusetts	1	0	2	14	26	1	0	2	14	5	_	22	43	506	568
New Hampshire Rhode Island	_	0 0	2 1	5	9 2	_	0 0	2 0	5	9	_	2 0	36 17	98	38 12
Vermont [†]	_	0	1	2	4	—	0	0	—	2	2	1	14	83	69
Mid. Atlantic New Jersey	_	2 0	13 2	84 10	103 26	_	2 0	11 2	57 10	79 26	35	30 4	137 13	976 131	801 113
New York (Upstate)	_	0	7	28	30	_	0	5	5	11	27	12	123	392	302
New York City Pennsylvania	_	0 1	3 5	11 35	14 33	_	0 1	3 5	11 31	14 28	8	1 11	8 26	42 411	56 330
E.N. Central	1	3	11	81	101	1	2	6	58	85	24	50	133	1,061	2,287
Illinois	_	0	4 5	17	24 14	—	0 0	4	17 6	24 7	5	11	35 75	225	535 183
Indiana Michigan	_	1	3	15 17	14	_	0	3	9	11	4	4 7	23	135 238	138
Ohio Wisconsin	1	1 0	5 2	30 2	28 17	1	0 0	4 2	24 2	26 17	15	14 7	30 41	354 109	751 680
W.N. Central	_	1	4	40	54	_	0	3	14	24	11	, 41	552	741	1,796
Iowa	—	0	2	10	12	_	0	1	3	1	7	12	63	160	443
Kansas Minnesota	_	0 0	1 2	1 10	9 9	_	0 0	1 1	1 3	9 3		11 0	28 485	193 112	170 530
Missouri Nebraska†	—	0 0	2 2	12 5	18 4	—	0 0	1 1	3 3	8 3	1	8 4	42 10	186 65	266 177
North Dakota	_	0	1	1	—	_	0	1	1		3	0	26	16	77
South Dakota	_	0	1	1	2	—	0	0			_	0	7	9	133
S. Atlantic Delaware	_	3 0	14 1	122 4	154 2	_	1 0	7 1	51 4	63 2	33	21 0	46 1	592 3	888 14
District of Columbia	—	0	1		5	_	0	1		4	_	0	3	3	4
Florida Georgia	_	1 0	6 3	48 9	59 14	_	1 0	5 3	19 9	19 14	6	4 0	14 3	128 8	113 33
Maryland† North Carolina	_	0 0	2 11	7 22	14 22	_	0 0	1 3	1 6	1 5	3 22	3 0	9 21	81 131	134 64
South Carolina [†]	_	0	2	14	13	_	0	1	6	8	1	4	22	89	256
Virginia† West Virginia	_	0 0	4 2	14 4	20 5	_	0 0	3 0	6	8 2	1	2 0	27 9	126 23	238 32
E.S. Central	_	1	2	20	25	_	0	2	15	16	3	6	11	159	254
Alabama [†] Kentucky	_	0	1	4	4	_	0	1 1	4	3	_	1 0	4 5	46	51
Mississippi	_	0	1	1	.4	_	Ō	1	1	4	_	1	4	22	41
Tennessee [†]	_	0	2	15	17	_	0	2	10	9	3	2	10	91	162
W.S. Central Arkansas	_	1 0	23 3	41 7	85 11	_	0 0	6 2	16 5	20 3	_	21 2	360 21	377 45	1,336 185
Louisiana Oklahoma	—	0 0	1 4	2 8	26 13	_	0 0	1 0	1	4 2	_	0 0	3 124	3 18	37
Texas [†]	_	1	16	24	35	_	0	4	10	11	_	18	215	311	1,114
Mountain	—	1	5	41	66	—	0	4	19	17	26	64	230	1,769	2,574
Arizona Colorado	_	0 0	3 2	13 14	29 14	_	0 0	3 1	13 2	9	17	13 22	177 40	353 553	678 825
Idaho†	_	0	2 1	1	3	_	0 0	2 1	1	3	2	2 2	13	50	133 476
Montana Nevada†	_	0 0	2	3 2	7	_	0	1	1	1	_	0	14 9	80 38	36
New Mexico† Utah	—	0 0	1	2 4	3 10	_	0 0	1 0	_	2 2	7	2 16	6 39	50 596	133 264
Wyoming	_	0	2	2		_	0	2	2			1	8	49	204
Pacific	1	5	29	219	179	1	5	25	189	173	11	51	1,334	984	1,978
Alaska California	1	0 3	1 14	2 136	1 117	1	0 3	1 14	2 136	1 117	_2	2 30	15 1,136	42 589	31 822
Hawaii	—	0	1	5	10	_	0	1	5	5	—	2	6	42	114
Oregon [†] Washington	_	1 0	7 25	51 25	32 19	_	1 0	4 11	35 11	32 18	9	3 9	14 195	79 232	549 462
American Samoa	U	0	0	_	_	U	0	0	U	U	U	0	0	U	U
C.N.M.I. Guam	U	0 0	0 0	_	1	U	0 0	0 0	U	U 1	U	0 0	0 0	U	U 2
Puerto Rico	_	0	1	—	_	—	0	1	_	_	_	0	1	_	—
U.S. Virgin Islands	_	0	0	_	_	_	0	0	_	—	—	0	0	—	_

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005 (31st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-* Incidence data for reporting years 2005 and 2006 are provisional. * Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

(31st Week)*										Salmonellosis					
	Rabies, animal Previous				Roc	ку Mour Prev		tted fever	r	Previous					
	Current	52 w	eeks	Cum	Cum	Current	52 w	eeks	Cum	Cum	Current	52 \	veeks	Cum	Cum
Reporting area United States	week 78	104	Max 157	2006 3,195	2005 3,609	25	Med 35	Max 246	2006 893	2005 801	600	Med 781	Max 2,288	2006 18,969	2005 21,885
New England Connecticut Maine [†] Massachusetts New Hampshire	20 14 6 	11 3 1 4 0 0	26 13 4 17 3	344 100 44 154 9	439 99 42 235 10	 N 	0 0 0 0 0	2 0 0 2 1	2 N 1 1	4 	10 2 6	34 0 2 19 2	241 233 8 49 10	1,062 233 56 619 79	1,258 256 107 684 99
Rhode Island Vermont [†]	_	1	4 4	1 36	14 39	_	0	2 0	_	1	2	0 1	17 10	45 30	47 65
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	16 N 16 —	19 0 11 0 7	46 0 24 3 35	591 N 317 1 273	533 N 287 17 229	 	1 0 0 1	7 3 1 1 5	22 4 2 1 15	52 17 1 6 28	72 — 37 5 30	74 14 22 8 28	272 41 233 44 58	1,900 375 601 119 805	2,769 532 646 663 928
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	9 3 1 3 2 N	2 0 1 0 0	12 4 3 5 6 0	74 19 8 30 17 N	124 27 7 20 70 N		0 0 0 0 0	7 4 2 1 6 1	23 1 5 16 1	29 11 3 13 2	93 41 5 47 	94 26 12 16 23 16	219 53 67 35 50 44	2,607 591 400 488 688 440	3,229 1,149 295 547 729 509
W.N. Central Iowa Kansas Minnesota Missouri Nebraska† North Dakota South Dakota	2 1 	5 0 1 1 1 0 0 0	20 5 6 6 7 4	173 30 53 27 28 14 21	210 	2 1 	2 0 0 1 0 0 0	12 2 1 12 4 1 1	111 1 2 92 14 —	100 3 5 1 83 3 - 5	27 	44 7 10 15 3 0 2	106 18 17 60 40 12 46 8	1,369 216 191 389 402 106 10 55	1,429 240 211 319 419 125 15 100
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [†] North Carolina South Carolina [†] Virginia [†] West Virginia	19 — — — 16 — 3	36 0 0 4 8 8 4 10	118 0 99 9 14 22 10 27 13	1,208 — 105 98 207 281 91 362 64	1,359 201 171 220 313 135 293 26	21 — — 21 — 21 —	18 0 0 1 15 1 2 0	94 2 1 3 4 4 87 6 10 2	542 9 12 13 26 430 12 39 1	405 5 1 11 68 45 206 32 34 3	179 — 130 26 9 — 9 — 5	203 2 1 96 24 12 28 19 20 2	514 9 7 230 87 29 114 73 62 19	4,964 57 35 2,250 664 324 689 434 458 53	5,706 62 28 2,151 901 438 711 768 568 79
E.S. Central Alabama [†] Kentucky Mississippi Tennessee [†]	 	3 1 0 2	15 7 5 2 9	132 48 4 80	80 47 2 31	 	5 1 0 3	18 8 1 3 18	126 36 1 89	146 36 — 8 102	54 36 — 18	48 15 0 12 14	104 65 27 62 41	1,138 503 264 371	1,184 349 393 442
W.S. Central Arkansas Louisiana Oklahoma Texas [†]	7 4 3	14 0 0 1 12	34 3 0 9 29	474 24 — 48 402	592 25 — 59 508	1 1 —	1 0 0 0	161 32 1 154 3	42 29 — 6 7	41 21 5 5 10	26 14 12 	80 14 6 7 45	922 43 38 48 839	1,671 425 91 232 923	2,127 397 496 205 1,029
Mountain Arizona Colorado Idaho [†] Montana Nevada [†] New Mexico [†] Utah Wyoming	1 1	3 2 0 0 0 0 0 0 0	16 11 2 2 2 2 5 1	86 66 8 8 4 2	154 109 13 5 5 6 2 14		0 0 0 0 0 0 0 0 0	6 6 1 2 2 0 2 2 1	19 5 1 2 - 5 3 2	22 12 3 1 - 3 - 2	27 1 18 3 — 5	50 14 12 3 4 5 1	110 67 45 9 16 17 13 30 5	1,333 392 375 97 82 68 113 173 33	1,264 352 294 98 51 108 148 161 52
Pacific Alaska California Hawaii Oregon [†] Washington	4 4 U	4 0 3 0 0 0	15 4 15 0 4 0	113 13 91 9 U	118 1 114 U	1 1 N	0 0 0 0 0	1 0 1 0 1 0	6 4 2 N	2 - 2 N	112 1 84 _ 2 25	109 1 86 5 7 8	426 7 292 15 25 124	2,925 45 2,259 122 227 272	2,919 31 2,193 167 250 278
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands	U U —	0 0 0 0	0 0 3 0	U U 	U U —	U U N	0 0 0 0	0 0 0 0	U U N	U U N	U U —	0 0 0 0	2 0 3 25 0	U U —	1 U 27 —

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005 (31st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

* Incidence data for reporting years 2005 and 2006 are provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(31st Week)*	Shiga toxin-producing <i>E. coli</i> (STEC) [†]						Sł	nigellosis		Streptococcal disease, invasive, group A					
	Previous			us			Prev	ious	,			Previous			TOUP A
Reporting area	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005
United States	55	53	297	1,141	1,331	136	203	1,002	5,330	7,478	40	85	282	3,130	3,079
New England	3	3	30	114	118	—	4	39	142	168		5	14	151	191
Connecticut Maine [§]	1	0 0	29 5	29 6	30 18	_	0 0	33 3	33 3	28 8		0 0	3 2	U 12	73 11
Massachusetts New Hampshire	1	1 0	9 2	59 12	46 11	_	3 0	9 4	93 5	109 4	_	3 0	6 9	94 32	79 12
Rhode Island Vermont [§]	_	0 0	2 2	2 2	2 11	_	0 0	6 2	5 3	9 10	_	0 0	3 2	4 9	7 9
Mid. Atlantic New Jersev	1	5 0	107 7	72 3	164 34	8	14 4	72 16	357 145	721 208	6	15 2	43 7	542 87	657 138
New York (Upstate)	_	1	103	19	64	8	4	60	139	163	3	4	32	225	187
New York City Pennsylvania	_	0 0	2 8	3 3	9 57	_	2 2	14 48	27 46	265 85	3	1 5	5 13	13 217	128 204
E.N. Central	11	10 1	38 10	233 33	265 75	8	20 7	96 26	504 148	572 172	10	16 4	43 10	582 111	650 216
Indiana	4	1	6	33	29	6	2	56	84	46	3	2	11	85	63
Michigan Ohio	7	1 3	7 14	38 76	56 52	1 1	3 3	10 11	99 94	151 54	3 4	3 4	12 19	159 185	159 141
Wisconsin W.N. Central	9	2 7	15 35	53 182	53 204	— 11	3 33	10 78	79 798	149 758	_	1 5	4 57	42 231	71 195
Iowa	1	2	10	63	45	—	1	7	39	52 83	Ν	0	0	N	N
Kansas Minnesota	8	0 3	4 19	100	19 38	2 1	4 2	20 8	69 60	49	_	1 0	5 52	43 110	33 70
Missouri Nebraska§	2	2 1	9 5	91 27	58 28	4	17 2	70 11	476 48	503 47	_	1 0	5 4	45 20	52 17
North Dakota South Dakota	_	0 0	15 5	16	1 15	4	0 3	3 17	12 94	2 22	_	0 0	5 3	7 6	6 17
S. Atlantic	4	7	39	193	186	51	53	122	1,470	1,102	12	21	41	751	605
Delaware District of Columbia	_	0 0	1 1	1	3	_	0 0	2 2	5 6	8 8	_	0 0	2 2	7 9	2 7
Florida Georgia	1 1	2 1	29 6	54 44	61 22	33 8	27 16	66 38	716 483	543 271	5 1	5 4	16 11	183 136	159 123
Maryland [§] North Carolina	2	1 1	5 11	25 45	32 22	7 1	2 1	10 22	64 97	43 104	2 4	3 1	12 26	136 121	122 84
South Carolina§	_	0	2	4	4 41		1	9	61 36	59 66	_	1 2	6 11	50 88	29 61
Virginia [§] West Virginia	_	0	2	_	1	2	1 0	1	2		_	0	6	21	18
E.S. Central Alabama [§]	5 2	2 0	10 4	63 15	54 19	5 4	8 3	22 14	226 121	668 173	N	3 0	9 0	113 N	100 N
Kentucky Mississippi	_	0	5	_	4		0	12 6	36	50	_	0	2 0	_	_
Tennessee§	_	1	4	25	31	1	3	11	69	445	—	3	9	113	100
W.S. Central Arkansas	1	1 0	52 2	14 6	54 8	10 2	26 1	596 7	470 52	2,084 33	2 1	7 0	58 5	251 21	206 12
Louisiana Oklahoma	1	0	1 8		16 14	8	0 3	11 286	4 62	91 431	1	0	1 14	1 71	4 77
Texas [§]	—	1	44	43	16	_	22	308	352	1,529	_	4	43	158	113
Mountain Arizona	7 1	5 1	15 8	123 49	145 16	12 1	19 11	47 29	473 271	376 195	10 5	11 5	78 57	450 238	408 173
Colorado Idaho§	6 3	1 1	6 7	39 31	34 21	11	3 0	18 4	78 9	56 7	3	3 0	8 2	95 7	131 2
Montana	_	0	2	_	8	—	0	1	4	5	_	0	0	_	1
Nevada§ New Mexico§	_	0 0	3 3	8 4	13 18	_	1 2	8 9	28 46	34 54	1	0 1	6 7	54	58
Utah Wyoming	1	1 0	7 3	38 6	32 3	_	1 0	4 1	36 1	23 2	1	1 0	6 1	53 3	40 3
Pacific	14	7 0	55	147	141 9	31	40 0	148	890	1,029	_	2	9 0	59	67
Alaska California	8	4	1 18	98	60	29	32	2 104	7 710	10 864	_	0	0	_	_
Hawaii Oregon [§]	_	0 2	4 47	6 41	4 45	_	1	4 31	23 77	16 77	N	2 0	9 0	59 N	67 N
Washington	6	2	32	43	23	2	2	43	73	62	N	0	0	N	Ν
American Samoa C.N.M.I.	U U	0 0	0 0	U U	U U	U U	0 0	2 0	U U	3 U	U U	0 0	0 0	U U	U U
Guam Puerto Rico	_	0 0	0 0	_	_	_	0 0	3 2	_	10	N	0 0	0 0	N	N
U.S. Virgin Islands	_	Ő	Ő	—	_	—	Ő	0	_	—		Ő	Ő	_	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005 (31st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No N: Not notifiable.

Cum: Cumulative year-to-date counts.

Max: Maximum.

Med: Median.

¹ Incidence data for reporting years 2005 and 2006 are provisional.
 ¹ Incidence *E. coli* O157:H7; Shiga toxin positive, serogroup non-0157; and Shiga toxin positive, not serogrouped.
 ⁸ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(31st Week)*	Strepto		neumonia resistant,	e, invasive all ages	disease	Sypl	Syphilis, primary and secondary						Varicella (chickenpox)					
		Prev	vious				Previ	ous				Prev	vious	. ,				
Reporting area	Current week	52 w Med	eeks Max	Cum 2006	Cum 2005	Current week	<u>52 we</u> Med	eks Max	Cum 2006	Cum 2005	Current week	52 w Med	veeks Max	Cum 2006	Cum 2005			
United States	37	50	334	1,654	1,756	120	160	334	4,701	4,938	163	800	3,204	27,665	17,803			
New England		1	24	16	162	3	4	17	125	117		43	144	1,002	3,578			
Connecticut Maine [†]	U N	0 0	7 0	U N	68 N	3	0 0	11 2	28 7	24 1	U	0 5	58 20	U 151	1,012 210			
Massachusetts New Hampshire	_	0 0	6 0	_	71	_	2 0	5 2	74 7	78 8	_	8 5	54 43	92 265	1,618 201			
Rhode Island	_	0	11	6	14	_	0	6	7	6	_	0	0	_	_			
Vermont [†]	_	0	2	10	9		0	1	2	_		12	50	494	537			
Mid. Atlantic New Jersey	1 N	3 0	15 0	111 N	155 N	13 6	17 2	35 7	456 95	620 85	15	105 0	183 0	3,203	3,150			
New York (Upstate) New York City	1 U	1 0	10 0	41 U	62 U	4	2 7	14 21	90 123	41 390	_	0 0	0 0	_	_			
Pennsylvania	_	2	9	70	93	3	5	9	148	104	15	105	183	3,203	3,150			
E.N. Central	9	11	41	403	440	10	17	38	506	524	50	213	586	10,031	3,775			
Illinois Indiana	4	1 2	3 21	13 109	18 143	2	9 1	23 4	246 35	281 40	N	1 0	6 347	35 N	61 70			
Michigan Ohio	5	0 6	4 32	16 265	28 251	3 5	2 4	19 8	67 127	53 128	9 41	102 82	174 420	3,008 6,417	2,387 954			
Wisconsin	Ň	0	0	205 N	N		1	4	31	22	—	12	52	571	303			
W.N. Central Iowa	N	1 0	191 0	33 N	30 N	_	4 0	9 3	144 9	161 5	2 N	22 0	84 0	1,004 N	262 N			
Kansas	N	0	0	N	N	_	0	2	12	13	2	0	1	3	_			
Minnesota Missouri	_	0 1	191 3	33	24	_	1 3	3 8	21 99	51 89	_	0 17	0 82	940	173			
Nebraska [†]	—	0	0	—	2	_	0	1	1	3	—	0	0	_	12			
North Dakota South Dakota	_	0	1 0	_	1 3	_	0 0	1 2	2	_	_	0 1	25 12	27 34	77			
S. Atlantic	27	24	53	903	730	36	42	186	1,139	1,168	34	90	860	2,980	1,375			
Delaware District of Columbia	_	0 0	2 3	21	1 13	1 4	0 1	2 9	15 68	8 66	2	1 0	5 5	44 23	22 23			
Florida Georgia	19 8	13 7	36 29	494 300	395 236	14	15 8	29 147	437 144	415 213	_	0 0	0 0	_	_			
Maryland [†]	_	0	0	_	_	1	5	19	173	192	_	0	0	_	_			
North Carolina South Carolina [†]	N	0 0	0 0	N	N	8 2	5 1	17 7	171 41	153 36	3	0 16	0 52	745	355			
Virginia† West Virginia	N	0 1	0 14	N 88	N 85	6	2 0	12 1	89 1	83 2	25 4	28 26	812 70	1,151 1,017	289 686			
E.S. Central	_	3	13	109	101	5	10	20	337	252	- -	0	70	69	20			
Alabama [†] Kentucky	N	0	0	N	N	1	4 0	12 3	147 1	95	N	0	70 0	69 N	20 N			
Mississippi	_	0	0	_	1	1	0	6	35	31	_	0	0	_	_			
Tennessee [†]	_	3	13	109	100	3	5	13	154	126	N	0	0	N	N			
W.S. Central Arkansas	_	0 0	4 3	13 11	98 12	34	26 0	41 6	889 40	751 31	52	197 6	1,757 110	7,572 562	3,881			
Louisiana Oklahoma	N	0 0	4 0	2 N	86 N	4 2	4 1	17 6	133 42	167 25	_	0 0	8 0	40	108			
Texas [†]	N	Ő	Ő	N	N	28	20	29	674	528	52	177	1,647	6,970	3,773			
Mountain	N	1	27	66	40 N	4	7	17	217	258	10	52	138	1,804	1,762			
Arizona Colorado	N	0	0 0	N N	N N	4	4 1	13 3	105 23	86 27	9	0 33	0 76	955	1,198			
Idaho† Montana	N	0 0	0 1	N	N	_	0 0	1	2 1	20 5	_	0 0	0 0	_	_			
Nevada [†]	_	0	27	4	2	_	1	12	44	79	—	0	2	4				
New Mexico† Utah	_	0 0	1 8	1 28	17	_	1 0	5 1	37 5	34 7	1	3 10	34 55	284 531	154 365			
Wyoming		0	3	33	21		0	0	_		—	0	8	30	45			
Pacific Alaska	_	0 0	0 0	_	_	15	32 0	49 4	888 5	1,087 5	_	0 0	0 0	_	_			
California Hawaii	N	0 0	0	N	N	5	28 0	42 2	742 12	976 6	N	0 0	0 0	N	N			
Oregon [†]	Ν	0	0	Ν	Ν	_	0	6	10	17	N	0	0	N	N			
Washington	N	0	0	N	N	10	2	11	119 U	83	N	0	0	N	N			
American Samoa C.N.M.I.	_	0 0	0 0	_	_	U U	0 0	0 0	U U	U U	U U	0 0	0 0	U U	U U			
Guam Puerto Rico	N	0 0	0 0	N	N	_	0 0	0 9	_	3	_	2 0	12 24	_	376			
U.S. Virgin Islands	_	0	0		_	_	0	0	_	_	_	0	0	_	_			

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005 (31st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No

Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to- Incidence data for reporting years 2005 and 2006 are provisional. Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(31st Week)*					M/							
			Neuroinvas	ive	West Nile vir	rus disease						
			vious			_	Non-neuroinvasive Previous					
Reporting area	Current week	<u>52 v</u> Med	veeks Max	Cum 2006	Cum 2005		urrent week	<u>52 w</u> Med	eeks Max	Cum 2006	Cum 2005	
United States	3	1	155	84	330		9	0	203	102	525	
New England	_	0	3	_	_		_	0	2	_	_	
Connecticut Maine [§]	_	0 0	2 0	_	_		_	0 0	1 0	_	_	
Massachusetts	_	0	3	_	_		_	0	1	_	_	
New Hampshire	_	0 0	0	_	—		—	0 0	0 0	_	—	
Rhode Island Vermont [§]	_	0	1 0	_	_		_	0	0	_	_	
Mid. Atlantic	_	0	10	4	2		_	0	4	_	4	
New Jersey New York (Upstate)	_	0 0	1 7	_	_		_	0 0	2 2	_	_	
New York City	_	0	2	1	_		_	Ö	2	_	_	
Pennsylvania	—	0	3	3	2		—	0	2	—	4	
E.N. Central	—	0	39	2	32		_	0	18	—	23	
Illinois Indiana	_	0 0	25 2	1	20 1		_	0 0	16 1	_	22	
Michigan	—	0	14	1	1		—	0	3	_	—	
Ohio Wisconsin	_	0 0	9 3	_	8 2		_	0 0	4 2	_	1	
Wisconsin W.N. Central		0	26	20				0			130	
lowa	1	0	3	20	40		1	0	80 5	26 3	130	
Kansas		0	3	_	1		—	0	1	1	N	
Minnesota Missouri	1	0 0	5 4	6 1	4 5		_	0 0	5 3	3	7 1	
Nebraska§	_	0	9	4	10		_	0	24	4	22	
North Dakota South Dakota	_	0 0	4 7	8	5 15		1	0 0	15 33	5 10	21 76	
S. Atlantic	_	0	6	_	8		_	0	3	_	11	
Delaware	_	0	1	_	_		_	0	0	_	_	
District of Columbia Florida	_	0 0	1 2	_	6		_	0 0	1 2	_	9	
Georgia	_	0	3	_			_	0	3	_	1	
Maryland [§]	_	0	2	—	_		—	0	1	—	_	
North Carolina South Carolina [§]	_	0 0	1 1	_	1 1		_	0 0	1 0	_	1	
Virginia§	_	0	0	_			_	0	1	_	_	
West Virginia	—	0	0	_	_		Ν	0	0	Ν	Ν	
E.S. Central Alabama [§]	_	0 0	10 1	11	9 2		_	0 0	5 2	5	5 1	
Kentucky	_	0	1	_	_		_	0	0	_	_	
Mississippi	—	0	9	11	7		—	0	5	5	4	
Tennessee	_	0	3	_	_		_	0	1	_		
W.S. Central Arkansas	_	0 0	32 3	20	86 2		_	0 0	22 2	_	47 5	
Louisiana	_	0	20	_	46		_	0	9	_	24	
Oklahoma Texas§	_	0 0	6 16	3 17	2 36		_	0 0	3 13	_	 18	
Mountain	2	0	16	20	25		8	0	39	60	53	
Arizona		0	8	2	8		_	0	8	2	13	
Colorado	_	0	5	3	3		_	0	13	8	28	
Idaho [§] Montana	_	0 0	2 3	6	1		8	0 0	12 9	38	1 1	
Nevada§	2	0	3	6	4		_	0	8	10	3	
New Mexico [§] Utah	_	0 0	3 6	3	5 4		_	0 0	4 8	2	3 3	
Wyoming	_	0	2	_	—		_	0	1	_	1	
Pacific	_	0	50	7	128		_	0	90	11	252	
Alaska	—	0	0	7	109		_	0	0			
California Hawaii	_	0 0	50 0		128		_	0 0	89 0	11	248	
Oregon§	—	0	1	—	_		—	0	2	—	4	
Washington	—	0	0	—	_		—	0	0	—	_	
American Samoa	U U	0	0	U U	U U		U U	0	0 0	U U	U U	
C.N.M.I. Guam	<u> </u>	0	0	_	_		_	0	0			
Puerto Rico	—	0	0	_	—		—	0	0	_	_	
U.S. Virgin Islands	—	0	0	—	—		—	0	0	—	—	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending August 5, 2006, and August 6, 2005 (31st Week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: No

N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median.

Max: Maximum.

* Incidence data for reporting years 2005 and 2006 are provisional. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance). S Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths in 122 U.S. cities,* week ending August 5, 2006 (31st Week)


TABLE III. Deaths	in 122 U.S. cities,* week ending August 5, 2006 (31st Week) All causes, by age (years)							All causes, by age (years)							
	All				-		P&I [†]		All						P&I [†]
Reporting Area	Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	Total	Reporting Area	Ages	<u>≥</u> 65	45-64	25-44	1-24	<1	Total
New England	487	331	83	43	17	13	36	S. Atlantic	1,076	657	287	84	27	21	53
Boston, MA Bridgeport, CT	128 27	71 17	17 5	27 1	9 3	4 1	9 4	Atlanta, GA Baltimore, MD	85 161	49 80	26 59	8 12	2 4	6	2 13
Cambridge, MA	13	10	3			_	-	Charlotte, NC	44	31	8	2	3		4
Fall River, MA	20	16	2	1	1	_	1	Jacksonville, FL	185	120	45	12	5	3	1
Hartford, CT	42	26	9	5	_	2	4	Miami, FL	76	46	18	7	3	2	4
Lowell, MA	25	24	1	—	—	—	3	Norfolk, VA	59	33	18	2	3	3	—
Lynn, MA	6	5	1	—	—	—		Richmond, VA	62	34	22	4	1	1	3
New Bedford, MA New Haven, CT	22 46	18 29	4 14	1	_	2	1 4	Savannah, GA	47	31	10	4	1	1	4 6
Providence, RI	40	29 34	6	2	2	2	4 5	St. Petersburg, FL Tampa, FL	53 174	33 127	9 32	8 15	2	1	11
Somerville, MA	40	3	1				_	Washington, D.C.	118	66	38	7	3	4	3
Springfield, MA	38	24	10	2	1	1	_	Wilmington, DE	12	7	2	3	_	_	2
Waterbury, CT	26	21	3	1	—	1	3	E.S. Central	852	549	202	55	25	21	47
Worcester, MA	44	33	7	3	1	—	2	Birmingham, AL	205	138	42	9	23	8	-47
Mid. Atlantic	2,084	1,389	475	140	48	31	93	Chattanooga, TN	73	40	24	5	_	4	2
Albany, NY	44	30	11	2	_	1	1	Knoxville, TN	103	69	22	10	2	_	6
Allentown, PA	25	17	6	1	1	—	1	Lexington, KY	55	31	16	4	3	1	2
Buffalo, NY	74	46	20	5	2	1	3	Memphis, TN	170	106	44	11	7	2	16
Camden, NJ	29 17	14 14	8 3	6	1	_	4	Mobile, AL	53 44	41	5	4	2	1	3
Elizabeth, NJ Erie, PA	45	36	5	2	_	2	4 5	Montgomery, AL Nashville, TN	149	28 96	13 36	3 9	3	5	10
Jersey City, NJ	31	19	8	_	3	1	_								
New York City, NY	1,069	716	248	62	26	16	33	W.S. Central	1,376	865	334	90	45	42	68
Newark, NJ	57	26	16	11	3	1	2	Austin, TX Baton Rouge, LA	90 39	51 23	25 10	8 2	4 2	2 2	1
Paterson, NJ	13	7	2	2	_	2	2	Corpus Christi, TX	39	22	11	1	3	2	1
Philadelphia, PA	332	204	81	36	7	4	19	Dallas, TX	182	110	41	13	8	10	9
Pittsburgh, PA [§] Reading, PA	18 32	10 25	5 6	1	1 1	1	2	El Paso, TX	69	38	19	11	_	1	8
Rochester, NY	137	108	20	7	1	1	9	Fort Worth, TX	129	89	28	3	1	8	6
Schenectady, NY	15	12	3	_		_	_	Houston, TX	336	207	82	33	11	3	25
Scranton, PA	22	17	5	_	—	_	1	Little Rock, AR New Orleans, LA ¹	87 U	50 U	24 U	5 U	4 U	4 U	1 U
Syracuse, NY	57	37	19	1		_	7	San Antonio, TX	222	149	52	7	7	7	8
Trenton, NJ	26	14	7	2	2	1	2	Shreveport, LA	73	49	16	3	4	1	5
Utica, NY Yonkers, NY	16 25	14 23	1 1	1 1	_	_	2	Tulsa, OK	110	77	26	4	1	2	4
								Mountain	967	593	240	88	28	17	56
E.N. Central Akron, OH	1,995 56	1,296 36	481 13	122 5	46 1	50 1	144 2	Albuquerque, NM	119	83	24	8	4	_	7
Canton, OH	29	18	9	2	_	_	4	Boise, ID	47	28	13	3	2	1	3
Chicago, IL	333	181	97	35	12	8	25	Colorado Springs, CO	43	25	15	1	2	_	4
Cincinnati, OH	82	52	16	8	4	2	10	Denver, CO	85	41	26	11	1 6	6 2	20
Cleveland, OH	187	138	36	5	2	6	5	Las Vegas, NV Ogden, UT	247 29	152 23	62 5	25 1	0		20
Columbus, OH	222	155	46	13	4	4	28	Phoenix, AZ	168	92	37	27	7	4	8
Dayton, OH Detroit, MI	133 155	96 80	27 48	5 15	1 4	4 8	12 8	Pueblo, CO	23	17	2	2	2	_	2
Evansville, IN	30	17	40 9	15	4			Salt Like City, UT	82	48	26	3	2	3	4
Fort Wayne, IN	57	38	17	2		_	2	Tucson, AZ	124	84	30	7	2	1	6
Gary, IN	15	7	6	2	_	_	1	Pacific	1,626	1,057	401	101	37	30	99
Grand Rapids, MI	39	23	10	4	1	1	1	Berkeley, CA	11	9	1		_	1	
Indianapolis, IN	182	105	52	14	6	5	12	Fresno, CA	181	116	45	17	3	_	9
Lansing, MI Milwaukee, WI	46 122	31 87	12 26	3 2	4	3	1 14	Glendale, CA Honolulu, HI	9 65	6 41	3 18	3	2	1	_
Peoria, IL	55	37	20	2	4	3	6	Long Beach, CA	99	69	21	4	2	3	14
Rockford, IL	61	46	11	1	1	2	4	Los Angeles, CA	210	124	52	19	6	9	18
South Bend, IN	53	44	8	_	_	1	4	Pasadena, CA	17	13	3	1	_	_	1
Toledo, OH	88	65	19	2	—	2	2	Portland, OR	101	67	23	6	2	3	2
Youngstown, OH	50	40	8	2	_	_	3	Sacramento, CA	199	129	53	9	5	3	10
W.N. Central	647	427	135	46	21	18	32	San Diego, CA	107 122	60 68	31 33	8 14	5 3	3 4	9 12
Des Moines, IA	126	93	19	9	4	1	10	San Francisco, CA San Jose, CA	213	151	33 49	14	3	4	12
Duluth, MN	34	28	4	2		_	2	Santa Cruz, CA	33	26	49	_	1		2
Kansas City, KS Kansas City, MO	20	12	3	2 9	1 3	2 3	5	Seattle, WA	111	71	28	8	4	_	6
Lincoln. NE	100 42	63 29	22 10	9	3	3	5 4	Spokane, WA	51	37	12	1	_	1	1
Minneapolis, MN	64	36	14	4	5	5	-	Tacoma, WA	97	70	23	3	1	—	3
Omaha, NE	81	57	20	2	1	1	6	Total	11,110**	7,164	2,638	769	294	243	628
St. Louis, MO	54	33	16	3	—	2	1								
St. Paul, MN	64	33	15	8	5	3	2								
Wichita, KS	62	43	12	5	1	1	2								

U: Unavailable.

U: Unavailable. —:No reported cases. Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. [†] Pneumonia and influenza.

¹Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. ¹Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted. ** Total includes unknown ages.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals August 5, 2006, with historical data



* No measles or rubella cases were reported for the current 4-week period yielding a ratio for week 31 of zero (0).
† Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Morbidity and 122 Cities Mortality Data TeamPatsy A. HallDeborah A. AdamsRosaline DharaWillie J. AndersonVernitta LoveLenee BlantonPearl C. Sharp

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read *SUBscribe mmwrtoc*. Electronic copy also is available from CDC's Internet server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/publications/mmwr. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *www.mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

Reference to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2006-523-056/40066 Region IV ISSN: 0149-2195